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Abstract 
Mast cells (MCs) are increasingly recognized as powerful sentinel cells responsible for 
modulating the early immune responses to a wide range of infectious agents. This protective 
role is attributable in part to their preponderance at the host-environment interface and their 
innate capacity to rapidly release modulators of immune cell trafficking, which promote the 
early recruitment of pathogen-clearing immune cells from the blood. However, host-adapted 
pathogens have been a critical threat to humans for a long time because they have evolved 
mechanisms directed at overcoming protective immunity.  
In this work, we outline how Salmonella enterica serovar Typhimurium has evolved a 
novel mechanism to inactivate peripheral MCs, resulting in limited neutrophil responses at 
infection sites during early stages of infection. Due to the delay in bacterial clearance at the 
point of entry, Salmonella are able to multiply and rapidly disseminate to distal sites. 
Suppression of local MC degranulation restricts the outflow of vascular contents into sites of 
infection, thus facilitating bacterial spread.  
We discovered that MC suppression is mediated by the Salmonella Protein Tyrosine 
Phosphatase (SptP), which shares structural homology with YopH, an effector protein expressed 
by plague-causing Yersinia pestis. Interestingly, SptP also shares homology with phosphatases 
found in MCs, and these phosphatases are also homologous to YopH. We show that YopH 
possesses the ability to suppress MCs like SptP, suggesting that this activity is common among 
some of the more virulent bacterial pathogens. The functionally relevant domain in SptP is its 
enzymatic site, which works by dephosphorylating the vesicle fusion protein N-ethylmalemide-
sensitive factor (NSF) and by blocking phosphorylation of Syk, which are located downstream 
and upstream of tyrosine phosphorylation signaling pathway in MCs, respectively.  
v 
Without SptP, oral challenge with S. Typhimurium fails to suppress MC degranulation 
and exhibits limited colonization of the mesenteric lymph nodes. Administration of SptP to sites 
of Escherichia coli infection markedly enhances its virulence. Thus, SptP-mediated inactivation of 
local MCs is a powerful mechanism utilized by S. Typhimurium to impede early innate immunity. 
This finding provides a logical explanation for why previous attempts by others to demonstrate a 
protective role for MCs against Salmonella infection have given equivocal results.  
Taken together, this work highlights an overlooked virulence mechanism possessed by 
certain host-adapted pathogens to avoid the host innate immune system. Additionally, this 
innate immune-quelling property of SptP may hold future promise for tempering harmful 
inflammatory disorders in immune competent hosts.    
vi 
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1. Introduction to Mast Cells and Salmonella  
1.1 Mast Cell Regulation of Innate Immunity. 
1.1.1 Mast cells as Pivotal Immune Surveillance Cells  
After heart diseases, microbial infections are the second most common cause of human 
death in the world [2]. MCs have several innate properties that make them uniquely able to 
contribute to immune surveillance against infectious agents. These properties include their 
selective location in relatively large numbers immediately underneath the epithelial surface of 
the skin and the mucosa of the genitourinary tract and respiratory tract (Figure 1). Because 
these sites are typically where infections begin, MCs appear strategically located to be among 
the first immune cells that pathogens encounter after they have breached the epithelial barrier. 
MCs are also found in close proximity around peripheral blood and lymphatic vessels (Figure 2), 
and thus they are also ideally positioned to recruit immune cells from blood vessels into infected 
tissue or coordinate the movement of immune cells from infected sites into lymphatic vessels 
leading to the draining lymph nodes [3,4]. Recently, it was reported that MCs proximal to blood 
vessels constantly sample blood contents by employing cytoplasmic protrusions [5] suggesting 
that these cells are also capable of detecting and interacting with blood borne pathogens.  
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Figure 1. Strategic location of mast cells at the host-environment Interface 
(A) Nasal passage from mouse was dissected and cryosectioned longitudinally. (Upper 
panel) MCs, B cells, and lymphatics were stained with avidin, anti-B220, and anti-LYVE-
1 antibodies, respectively. (Bottom left panel) Macrophages were stained with anti- 
F4/80 antibody. Respiratory epithelial cells were visualized with autofluorescence and 
covered with fluorescent ovalbumin by nasal challenge. (Bottom right panel) DCs and B 
cells were stained with anti-CD11c and anti-B220 antibodies. Respiratory epithelial 
cells were also visualized with autofluorescence. L indicates airway lumen. (B) Bladder 
tissue was dissected and whole-mount-stained with wheat germ agglutinin, avidin, and 
anti-CD31 antibody for superficial epithelial cells, MCs, and blood vessels, respectively. 
The image is a 3D reconstruction view from Z-stacked images taken by confocal 
microscope. Scale bar: 300 µm. 
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Figure 2. MC proximity to blood and lymphatic vessels. 
Abundant MCs are found near blood vessels in the mouse ear (left). Red fluorescence 
identified cells are MCs stained with avidin. Blue represents blood vessels stained 
with anti-CD31 antibody. Green depicts fluorescent dextran (150 kDa). When these 
MCs undergo degranulation, they induce blood vessel leakage that can be detected by 
the exudation of fluorescent dextran from blood vessels, indicated by green particles 
located in interstitial spaces, arrow. MCs are also typically found near lymphatics 
(right). Blue depicts lymphatic vessels stained for LYVE-1. Green depicts B cells 
stained with anti-B220 antibody. Red depicts MCs stained with avidin. Scale bar: 10 
μm 
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1.1.2 Mast Cells Respond Rapidly to Invading Pathogens Through 
Degranulation. 
MCs are highly specialized for the synthesis and secretion of a myriad of 
pharmacologically-active products. MC mediators have traditionally been divided into two major 
groups: those that are preformed, which include histamine, heparin, serine proteases, some 
select cytokines and chemokines such as tumor necrosis factors (TNFs) [6]  and CXCL1/CXCL2 [7], 
and those that are synthesized de novo when the cells are activated, which include a wide range 
of cytokines and eicosanoids such as leukotrienes, prostaglandins and the thromboxanes [8]. 
The release of pre-packaged mediators into the surrounding tissue typically occurs beginning 
within seconds to minutes following stimulation, a strategy that gives MC-derived products a 
temporal advantage over those produced by other immune surveillance cells, which take 
markedly longer. The prepackaged MC products can be released in an explosive fashion or 
piecemeal.  
Piecemeal degranulation consists of a slow emptying of granule chambers in the 
absence of large scale intergranular fusion. Because of their longevity, MCs at sites of 
inflammation can undergo multiple cycles of degranulation followed by re-granulation; in this 
way MCs are able to sustain inflammatory responses to pathogens. Unlike the degranulation 
response, which is initiated within seconds of MC activation, de novo synthesis of eicosinoids, 
cytokines and chemokines occurs significantly later, with a time frame that is comparable to 
when other immune cells secrete their mediators following activation. Many studies have 
shown that de novo production of these mediators by MCs in response to pathogens can vary 
greatly depending on the stimulus and the experimental conditions. 
5 
1.1.3 Mast Cells Express a Wide Array of Receptors that Recognize a Broad 
Range of Pathogens. 
Like other immune cells involved in immune surveillance, MCs express a wide range of 
cell surface receptors that can directly bind pathogens, secreted toxins, or other microbial 
products. These receptors include most pattern recognition receptors (PRRs) as well as other 
receptors that specifically recognize microbial cell surface components. One of the best studied 
bacterial receptors on MCs is CD48, a GPI-anchored protein that binds type I fimbriae on various 
enterobacteria and a cell surface component on Mycobacterum tuberculosis [9,10]. Cross-linking 
of CD48 not only causes MC degranulation but also uptake of adherent bacteria. Additionally, 
MCs also express receptors on their cell surface for host proteins that coat pathogens, such as 
complement fragments and antibodies [11]. Depending on the receptor that is engaged, their 
cross-linking can trigger extensive or piece-meal MC degranulation. For example, cross-linking of 
CD48 by type I fimbriated E. coli can result in extensive MC degranulation and release of a wide 
range of mediators, whereas activation of Toll-like receptor (TLR) 4 by lipopolysaccharide (LPS) 
results in the significant secretion of soluble mediators but little or no MC degranulation. 
Similarly, binding of cholera toxin to the ganglioside GM1 results in the significant secretion of 
interleukin-6 (IL-6) but no accompanying degranulation of MCs [12].  
MC activation during infection is not always the result of contact with an infectious 
agent, its products or with opsonized microbes; many infected or otherwise stressed cells 
release danger signals or alarmins that serve as potent activators of MCs [13,14].  Therefore, 
MCs do not have to be in immediate proximity to a site of infection to contribute to the immune 
response. The signaling agents released by stressed host cells range from antimicrobial peptides 
and adenosine triphosphate (ATP) to IL-33, which is typically released when cells degrade [15]. 
Binding of any of these cellular products to MCs can trigger extensive MC degranulation. 
6 
1.1.4 Signaling Events in Mast Cells that Regulate Mast Cell Exocytosis. 
Despite the large body of information regarding immune recognition receptors for 
pathogens or their products found on MCs, the question of how MCs signal intracellularly to 
induce a secretory response remains largely unknown. However, several key signaling events are 
likely shared with the well-characterized IgE signaling pathway, which is triggered when 
allergens bind and crosslink IgE bound to the high-affinity IgE receptor (FcεRI) on MCs [16]. As 
Figure 3 demonstrates, when FcεRI receptors aggregate, they initiate a cascade of tyrosine 
phosphorylation events via multiple signaling molecules in the MC cytoplasm. Early on, activated 
Lyn kinase phosphorylates tyrosine residues at immunoreceptor tyrosine-based activation 
motifs (ITAMs) on the receptor subunits [16,17]. Subsequent amplification of tyrosine 
phosphorylation occurs through activation of Syk kinase, which phosphorylates another 
substrate, linker for activation of T cells (LAT) [17,18]. LAT phosphorylation activates 
Phospholipase γ1 (PLCγ1), leading to the cleavage of phosphatidylinositol into inositol 
trisphosphate (IP3) and diacylglycerol (DAG) [20,21]. DAG activates Protein Kinase C (PKC) and 
inositol triphosphate (IP3), which in turn releases calcium from the endoplasmic reticulum (ER) 
into the cytoplasm. This free calcium is utilized in the final stages of degranulation for the direct 
fusion of granules into plasma membrane. For degranulation and extracellular release of MC 
granules, fusion between granule membrane and plasma membrane must occur. V-soluble NSF 
(N-ethylmaleimide-sensitive factor) attachment protein receptor (v-SNARE/VAMP8) on the 
granule membrane and t-SNARE (SNAP-23) on the plasma membrane form stable trans-SNARE 
complexes to guide secretory vesicles to the plasma membrane [22,23]. Additionally, multiple 
accessory proteins are required to regulate cognate fusion processes and to assist in the 
formation of various protein complexes. As in the early signaling events that occur around the 
7 
receptor, tyrosine phosphorylation is also important in regulating the final exocytic events. NSF, 
an ATPase and vesicle-fusion regulator, is one accessory protein of interest [24,25]. It is believed 
that timely dephosphorylation of tyrosine phosphorylated NSF helps to assemble and 
disassemble the SNARE fusion complexes, regulating granule size and degranulation events. 
While many of these signaling substrates may be involved in the MC degranulation responses to 
antibody-coated bacteria or type I fimbriated enterobacteria, only a portion of the substrates 
may be involved in the cytokine response to LPS, for which mediator release is not accompanied 
by degranulation. 
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Figure 3. Schematic of the signaling pathway associated with the Fcε receptor 
on mast cells. 
Top panel of image shows that antigen binding to the Fcε receptor induces the 
phosphorylation of Syk, amplifying signaling to induce degranulation and cytokine 
and lipid mediator release. Middle panel of image shows the brief signaling events 
during IgE receptor-mediated MC degranulation. Bottom panel of image shows the 
signaling events invovled in secretory vesicle fusion during degranulation. PTP-
MEG2 (protein tyrosine phosphatase megakaryocyte 2) dephosphorylates the 
vesicle-fusion regulator NSF (N-ethylmaleimide-sensitive factor), which is a 
prerequisite to induce granule fusion to the plasma membrane.   
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1.1.5 Physiological Consequences of MC Degranulation. 
Although MCs produce antimicrobial agents that directly reduce the microbial burden in 
the body, for the most part the antimicrobial role of MCs appears to involve the mobilization of 
other immune cells to combat infection. The MC response to microbial challenge is typically 
biphasic. First, rapid degranulation facilitates the release of pre-formed inflammatory mediators, 
including TNF-α, proteases, and histamine, that initiate the early recruitment of immune cells to 
sites of infection [26]. This initial response is followed by de novo synthesis and secretion of 
various immune mediators several hours later. This biphasic response permits MCs not only to 
initiate but to sustain critical immune responses for prolonged periods of time. Because MCs are 
found in close proximity to the vasculature, many MC-derived mediators readily traffic into the 
bloodstream, initiate blood vessel dilation, and promote the extravasation of various immune 
cells [27,28]. The functional importance of MCs has been best studied following bacterial 
infections. The protective role of MCs and MC-derived TNF was first demonstrated nearly two 
decades ago against Klebsiella pneumoniae infection [29] and against polymicrobial intra-
abdominal sepsis [30]. Upon contact with bacteria, MCs release TNF-α, which initiates the early 
recruitment of neutrophils to clear the pathogen.  
MCs have been shown to play similar protective roles during Pseudomonas aeruginosa 
infection of the mouse peritoneum [31], E. coli infection of the peritoneum and urinary tract 
[32], Citrobacter rodentium [33] and Helicobacter felis [34] infections of the gastrointestinal 
tract, and Haemophilus influenzae infection of the  ear [35]. MCs are equally effective against 
several Gram-positive bacteria, including Streptococcus pyogenes, Mycoplasma pulmonis [36], 
Mycoplasma pneumonia and Listeria monocytogenes [37]. Table 1 shows various pathogenic 
10 
bacteria that infect humans and summarizes the protective effects of MCs exerted against these 
pathogens.  
 
Table1. Diverse physiological reactions of MCs to various pathogenic bacteria 
 Pathogenic bacteria are grouped by Gram-stain reaction. Each bacterium is categorized 
by corresponding MC mediators and their effects on the immune system. ND: not 
determined. 
 
 
 
 
Gram Stain 
Reaction 
Pathogenic Bacteria 
MC 
mediators 
Physiological Consequences References 
Gram- 
Negative 
Klebsiella pneumoniae TNF-α, IL-6 Recruitment of neutrophils [29], [38] 
Escherichia coli TNF-α 
Recruitment of neutrophils / DCs 
/ T cells 
[32], [39] 
[40], [30] 
Escherichia coli Leukotriene Recruitment of neutrophils [41] 
Citrobacter rodentium ND 
Antibacterial activity  
by directly killing bacteria in vitro 
[33] 
Francisella tularensis IL-4 
Alternative activation of Mφ for 
host resistance 
[42], [43] 
Pseudomonas 
aeruginosa 
IL-1 α/β Recruitment of neutrophils [44], [45] 
Gram-
Positive 
Clostridium difficile IL-8 Recruitment of neutrophils [46], [47] 
Group A streptococcus Cathelicidin Secreting antimicrobial peptides [48] 
Mycoplasma pneumonia ND Enhanced bacterial clearance [36] 
Listeria monocytogenes TNF-α Recruitment of neutrophils [49], [50] 
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MCs in peripheral tissue are activated upon contact with Dengue virus, and in response 
they release diverse cytokines and chemokines to recruit natural killer (NK) and NK T cells to 
clear the virus [51-54]. It is not necessary for virus to infect MCs in order to activate them. Viral 
components such as the protein Fv and synthetic viral double-stranded ribonucleic acid (dsRNA) 
effectively activate MCs [55,56] and as a result can elicit the recruitment of CD8+ T cells [57]. 
Although it is unclear whether MCs contribute to the clearance of human immunodeficiency 
virus (HIV), it appears that these cells become infected and serve as reservoirs, contributing to 
persistent HIV infection [58-60].  
Upon contact with cell surface components of various fungi, MC de novo synthesize and 
secrete selected mediators without extensive degranulation [61]. During Aspergillus [62] and C. 
neoformans infections [63], MC products promote significant anti-fungal innate immunity, which 
mostly involves the recruitment of phagocytic cells and other immune cells. A powerful MC-
mediated mechanism to reduce the burden of gut parasites such as N. brasiliensis [64], 
Trichinella spiralis and Strongyloides which is independent of immune cell recruitment, occurs 
via through the release of MC protease, which triggers smooth muscle contraction.  
 
1.2 Salmonella Typhimurium  
1.2.1 Salmonella Typhimurium: a Pathogenic Bacteria Involved in Food 
Poisoning. 
Salmonella Typhimurium is a highly invasive pathogen and a leading cause of foodborne 
illness [65]. The global burden of nontyphoidal Salmonella in terms of human health is as high as 
93.8 million cases, but because many mild cases are not diagnosed, the number is likely much 
higher [66].  S. Typhimurium virulence has been associated with the ability to evade and 
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suppress the host immune system. Some of the earliest studies investigating the pathogenesis 
of S. Typhimurium highlighted its remarkable capacity to invade and persist intracellularly within 
gut epithelial cells and neighboring macrophages (Mφs) [67], where it can replicate while 
avoiding immune cells and antimicrobial agents. Invasion and intracellular persistence are 
mediated by a variety of effector proteins encoded in S. Typhimurium pathogenicity islands 1 
and 2 (SPI-1 and SPI-2); the majority of these are exported out of the bacterial cell by the well-
characterized type III secretion system (T3SS) [68] (Figure 4).  
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Figure 4. Salmonella spp. utilizes the type III secretion system to achieve 
successful invasion and intracellular survival 
Salmonella secrete virulence effector proteins through the type III secretion 
system (T3SS), which is encoded in the Salmonella pathogenicity island 1 (SPI1), 
into the cytoplasm of host cells. Some virulence proteins (SipA, SipB, SipC, SopE 
and SopB) induce the rearrangement of the actin cytoskeleton, leading to bacterial 
uptake. Other virulence proteins (SopE, SopE2, and SopB) can activate the 
mitogen-activated protein kinase (MAPK) signaling pathway, which promotes pro-
inflammatory cytokine secretion. Additionally, SopB destabilizes tight junctions by 
stimulating Cl- secretion to permit basolateral migration of neutrophils. 
Interestingly, along with the proinflammatory response during Salmonella 
infection, AvrA inhibits NF-κB mediated activation of the proinflammatory 
response. Down-regulation of the inflammatory response also occurs via SspH1. 
SptP fulfills dual functions by turning off MAPK signaling and reversing 
cytoskeleton rearrangement. 
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1.2.2 Salmonella Typhimurium can Impede the Development of Adaptive 
Immune Responses. 
More recently, S. Typhimurium was found to directly suppress host adaptive immune 
responses by impeding the actions of specific immune cells; for example, S. Typhimurium 
induces antigen-presenting cells to adopt distinct migratory paths [69-71] and restricts T cell 
proliferation and activation to limited regions of the body following infection [72,73]. Other 
studies have pointed to a more global mechanism for the suppression of adaptive immune 
responses that involves targeting the draining lymph node, which is the epicenter of the 
adaptive immune response [74]. S. Typhimurium has been shown to target and disrupt the 
architecture of lymph nodes by altering homeostatic chemokine gradients, resulting in aberrant 
immune cell trafficking and an ineffective memory response to the pathogen.  
1.2.3 Salmonella Typhimurium Evades Recognition by Immune 
Surveillance Cells. 
The surface modification of pathogenic bacteria is a popular way to evade recognition 
by host surveillance cells, such as alteration of the carbohydrate capsule by Haemophilus 
influenza or Neisseria meningitides. Similarly, S. Typhimurium avoids the more immediate and 
non-specific host innate immune response. S. Typhimurium is capable of modifying lipid A 
expression on its surface; this is controlled by the PhoP/Q regulon. Regarding TLR4-mediated 
activation of the proinflammatory response, this altered surface lipid A expression is 100-fold 
less active than with the non-modified one [75,76]. 
1.2.4 Salmonella Typhimurium May Also Modulate the Innate Immune 
Response. 
An increasing number of studies have shown that S. Typhimurium evasion of recognition 
by host immune cells cannot explain the ability of S. Typhimurium to rapidly proliferate, as other 
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bacterial components such as flagella are readily recognized by the host PRR repertoire. The lack 
of an adequate innate immune response to control S. Typhimurium growth and spread suggests 
a more profound bacteria-mediated mechanism to delay or completely suppress non-specific 
host responses.  
To effectively achieve successful infection, S. Typhimurium has evolved virulence 
effector proteins to regulate host innate immune response. In particular, anti-inflammatory 
activity is beneficial to permit invading S. Typhimurium to achieve persistent infection. Although 
S. Typhimurium is known for inducing pro-inflammatory reactions in the host, recent reports 
suggest a role in suppressing pro-inflammatory responses in host as well. Several independent 
studies have reported that AvrA, acetyltransferase, inhibits the pro-inflammatory response and 
pro-apoptotic activity by modifying mitogen-activated protein kinase kinase, which leads to the 
inactivation of the c-Jun N-terminal kinase (JNK) signaling pathway [77,78]. These observations 
were made in intestinal epithelial cells and Mφs. In Mφs, AvrA was  found  to efficiently block 
the JNK signaling pathway and delay the death of Mφ, permitting the bacteria to establsh an 
intracellular niche [79].  
1.2.5 S. Typhimurium Survives Within Phagosomes to Establish Persistent 
Infections. 
After S. Typhimurium invades epithelial or phagocytic cells, it survives and replicates 
successfully in endocytic vesicles within the host cell. Infected Salmonella is detected inside 
Salmonella-containing vesicles (SCVs). Inside these SCVs, S. Typhimurium avoid the fusion of 
degradative vesicles by redirecting the vesicles and thus establish a Salmonella-favorable 
environment near ER without further maturation of phagosome. This establishment of 
Salmonella-favorable niche is accomplished via virulence effector proteins located in the SPI2 
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locus. These effector proteins prevent trafficking of NADPH oxidase- and intrinsic oxidase 
synthase (iNOS)-containing vesicles to SCVs [80-83]. Therefore, the failures of killing S. 
Typhimurium by resident Mφs and DCs at the submucosa lead to drain into mesenteric lymph 
nodes which connect bloodstream. Phagocytes harboring S. Typhimurium enter the blood 
stream and transport the bacteria into liver and spleen, eventually causing systemic infections 
[84]. The inability of phagocytes to eradicate Salmonella in phagosomes permits Salmonella to 
survive and disseminate systemically. 
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2. Salmonella Typhimurium Impedes Innate Immunity 
with a Mast Cell-Suppressing Tyrosine Phosphatase, SptP 
2.1 Introduction 
An important component of the innate immune response to bacterial pathogens is the 
MC, a morphologically distinct type of immune cell with specialized secretory functions that is 
preferentially located in close proximity to the epithelium of the gastrointestinal tract and other 
mucosal surfaces. Given their strategic location at potential sites of pathogen entry, MCs are 
among the first immune cells to perceive and react to microbial penetration of the epithelial 
barrier [3,4]. There is now a broad consensus that MCs are pivotal in initiating early innate 
immune responses to invading pathogens. Studies investigating Gram-positive and Gram-
negative bacteria as well as viruses and fungi [26,85] have revealed that MCs promote the early 
clearance of pathogens.  
However, to date, S. Typhimurium has proven to be an exception to this paradigm. 
Although some studies have indicated that MCs appear to contribute to S. Typhimurium 
clearance, the adoptive transfer of cultured MCs into MC-deficient mice does not significantly 
alter S. Typhimurium infection [86]. Furthermore, the presence of MCs during severe S. 
Typhimurium infection even appears harmful [87]. 
Given the inconclusive role of MCs during S. Typhimurium infection, here we sought to 
more closely examine interactions between MCs and S. Typhimurium in vitro and in vivo. We 
discovered that S. Typhimurium possessed a remarkable capacity to inhibit the ability of MCs to 
mount a degranulation response to powerful stimuli such as ionomycin and IgE-mediated 
antigen recognition and that this inhibition was attributable to SptP, a Salmonella protein 
tyrosine phosphatase secreted via the S. Typhimurium T3SS. Interestingly, SptP is structurally 
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analogous to several tyrosine phosphatases present in MCs and mediators found in other 
pathogens, such as YopH of Yersinia pestis. We determined that SptP appeared to 
dephosphorylate at least two proteins that are critical for MC degranulation. Our studies reveal 
the distinct ability of S. Typhimurium to inactivate a key modulator of host innate immunity and 
thereby facilitate stealthy infection. 
2.2 Results 
2.2.1 Failure of local MCs to degranulate and rapidly recruit neutrophils 
following S. Typhimurium infection 
MCs possess an apparent inability to evoke protective responses in mice following S. 
Typhimurium infection. To address this failure, we hypothesized that S. Typhimurium is able to 
inactivate MCs. In order to test this notion, we injected late log phase S. Typhimurium SL1433 
into the peritoneal cavity of WT and MC-deficient KitW-sh/KitW-sh (MC-deficient) mice. We chose 
the peritoneum for the following reasons: (i) it is a self-contained body site where bacterial 
numbers and neutrophil influx can be simultaneously and conveniently assessed, (ii) bacteria 
can directly interact with MCs, and (iii) MCs can be readily visualized in the peritoneal fluid in 
order to determine activation status by evaluating cell morphology. Interestingly, we observed 
no significant difference in the bacterial burdens of peritoneal lavage from WT and MC-deficient 
mice upon infection with S. Typhimurium (Figure 5A, top). Consistent with this finding, 
myeloperoxidase (MPO) assays with lavage fluid revealed no significant difference in neutrophil 
influx between the two groups of mice (Figure 5A, bottom). In contrast, when E. coli J96 was 
intraperitoneally injected into the two mouse strains, a significant difference in bacterial 
clearance was observed between WT and MC-deficient mice (Figure 5B, top). This observation 
correlated with an increased neutrophil influx in WT mice compared to MC-deficient mice 
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(Figure 5B, bottom). The lack of an appreciable difference in bacterial load between WT and MC-
deficient mice is consistent with previous reports that found no clear protective function for 
MCs during S. Typhimurium infection [87].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 5. S. Typhimurium fails to elicit neutrophil recruitment and 
bacterial clearance in vivo. 
(A, B, top) Residual bacterial counts (CFUs) in the peritoneal cavity of wild-type 
(WT) or MC-deficient mice 24 h following intraperitoneal (i.p.) infection with 
5×105 CFU S. Typhimurium or 1×107 CFU E. coli. (A, B, bottom) Myeloperoxidase 
assay with peritoneal lavage fluid from WT or MC-deficient mice 5 h post-
infection with 1×107 CFU S. Typhimurium or E. coli J96. Mean ± SEM, *p<0.05, 
N.S., not significant. 
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To determine whether our observations could be related to differential MC activation 
upon contact with different pathogens, we investigated the morphology of MCs in the 
peritoneal fluid (Figure 6A, top) and mesentery (bottom) of both groups of mice. For 
comparative purposes, we also examined MCs from PBS-injected mice. MCs from mice 
challenged with E. coli J96 were not readily visible with toluidine blue staining, as they were 
extensively degranulated with an observable spray of isolated granules around each MC (Figure 
6A, middle). In contrast, MCs from S. Typhimurium-challenged mice were readily detectable and 
fully granulated (Figure 6A, right) and morphologically resembled MCs from controls (Figure 6A, 
left). Quantification of fully and partially granulated MCs at both of these sites is provided in 
Figure 6B. These observations collectively suggest that, unlike their vigorous response to E. coli 
J96, MCs appear incapable of evoking a degranulation response to S. Typhimurium. 
Consequently, limited neutrophil responses and corresponding bacterial clearance were 
observed in S. Typhimurium-infected mice. 
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Figure 6. S. Typhimurium fails to elicit MC activation in vivo. 
(A) Morphologic appearance of MCs in the peritoneum (top) and mesentery (bottom) 
of WT mice 3 h after i.p. infection with 1×108 CFU S. Typhimurium or E. coli J96. Insets 
represent 60X magnification of MCs in the mesentery. Images represent 3 independent 
experiments. Top panels and inset scale: 20 µm. Bottom panels scale: 100 µm. n=4. (B) 
Granulated MC numbers in peritoneal lavages (left) or mesentery whole mounts 
(right) were quantified by counting the number of partially and fully granulated 
MCs/field (n=3-5; 5 random chosen fields). Wholly degranulated MCs could not be 
detected. Mean ± SEM, *p<0.05, **P<0.01, N.S., not significant. 
22 
2.2.2 S. Typhimurium Inhibited Degranulation of Murine MCs 
To more closely investigate the limited MC degranulation response to S. Typhimurium, 
we utilized the MC model cell line RBL-2H3 in standard in vitro β-hexosaminidase release assays 
to assess MC degranulation activity following exposure to S. Typhimurium, E. coli J96, or 
ionomycin, a potent MC secretagogue that works by triggering intracellular calcium flux [16]. 
Whereas ionomycin and E. coli J96 evoked significant responses, no degranulation was observed 
in response to S. Typhimurium or to PBS (Figure 7A). Compared to the dose-dependent MC 
degranulation observed with E. coli J96 (Figure 7B, left), the degranulation response to S. 
Typhimurium was minimal (Figure 7B, right).  
 
Figure 7. S. Typhimurium inhibited MC degranulation, but E. coli activated it. 
(A, B) In vitro β-hexosaminidase release assays with RBL cells after 1 h exposure to S. 
Typhimurium (STm) or E. coli J96. (B) Effect of bacterial multiplicity of infection (MOIs) 
(10:1, 100:1, 1000:1) on MC degranulation. Mean ± SEM, *p<0.001, **p<0.01, ***p<0.05, 
N.S., not significant.  
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2.2.3 S. Typhimurium Actively Suppresses Degranulation of Murine MCs 
The limited MC degranulation to S. Typhimurium could potentially be attributable to the 
ability of S. Typhimurium to actively block MC degranulation or to the inability of MCs to evoke a 
response to S. Typhimurium. To test the latter possibility, we exposed MCs to live and heat-
killed S. Typhimurium and observed that MCs failed to degranulate in response to either 
stimulus, indicating that the MCs were inherently unresponsive to S. Typhimurium (Figure 8A, 
left). Next, to investigate whether S. Typhimurium also possesses the ability to inhibit MC 
degranulation, we pre-treated MCs with live or heat-killed S. Typhimurium and then exposed 
the cells to the potent secretagogue ionomycin. We found that in contrast to killed S. 
Typhimurium, live S. Typhimurium was able to block subsequent MC responses to ionomycin 
(Figure 8A, right), indicating that S. Typhimurium has the innate capacity to actively block MC 
degranulation. To assess the specificity of this activity, we pre-treated MCs with live E. coli strain 
CI5 or the Gram-positive pathogen Staphylococcus aureus and found that neither of these 
bacteria were able to inhibit MC degranulation in response to ionomycin (Figure 8B).  
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2.2.4 S. Typhimurium Actively Suppresses Degranulation of Peritoneal 
MCs in vivo. 
In addition to in vitro experiments, we tested whether S. Typhimurium could also block 
the MC degranulation response to MC activators in vivo. Before we started the experiment with 
S. Typhimurium, we tested whether MC degranulation could be measured in vivo. To induce MC 
degranulation, we injected intraperitoneal (i.p.) Compound 48/80 (C48/80), a MC-specific 
activator, and performed double staining with an anti-c-kit antibody and avidin. As Figure 9A 
shows, a population of c-Kit+Avidin+ stained MCs were clearly visible in negative control mice, 
but this double-positive population dramatically decreased when C48/80 was injected. Based on 
Figure 8. S. Typhimurium pretreatment actively suppresses MC degranulation 
in response to MC secretagogues. 
(A, left) β-hexosaminidase release from RBLs following 1 h exposure to live or heat-
treated (60˚C, 1 h) Salmonella Typhimurium (STm). (A, right and B) RBL 
degranulation to ionomycin after 30 min pretreatment with (A, right) live or heat-
killed (HK)-STm, and to (B) various bacteria. Mean ± SEM, *p<0.001. 
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this in vivo model system, we first injected mice i.p. with S. Typhimurium or E. coli J96, and then 
injected the peritoneum with the MC-specific activator C48/80. The populations of c-Kit+Avidin+ 
stained MCs from mice administered C48/80 alone or C48/80 + E. coli J96 were depleted, while 
a significant portion of the MC population in mice administered C48/80 + S. Typhimurium was 
still present in the peritoneum (Figure 9B).  
 
 
 
 
 
 
Figure 9. S. Typhimurium suppresses peritoneal MCs in vivo. 
(A) Dose-dependent i.p. injection was performed with C48/80 (50 ug or 100 ug). (B) 
5x108 CFU of S. Typhimurium was injected i.p.. After 30 min, C48/80 (60 ug) was 
injected i.p. to activate MCs.  (A and B) After 30 min, the peritoneal fluid was stained 
with an anti-c-kit antibody and avidin for flow cytometry. Bar graph indicated the 
percent population of avidin+c-kit+ cells. Mean ± SD, *p<0.01. n=2-5 mice. N.S., not 
significant. 
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2.2.5 S. Typhimurium Actively Suppresses the Degranulation of Human 
MCs 
As our previous observations were made in a rodent cell line and mice in vivo, we 
sought to confirm them in the LAD2 human MC cell line. Pre-treatment of human MCs with S. 
Typhimurium not only blocked subsequent responses to ionomycin but also to other known 
secretagogues, C48/80 and complement fragment C5a (Figure 10). This suggests that S. 
Typhimurium possesses both the ability to circumvent MC activation and also the capacity to 
suppress the MC degranulation response to activators utilizing distinct signaling pathways, 
suggesting multipronged inhibitory activity.  
 
 
Figure 10. S. Typhimurium pretreatment suppresses human MC degranulation 
to MC secretagogues. 
Human mast cell (LAD2) degranulation in vitro was analyzed with a β-
hexosaminidase release assay in response to ionomycin (left), C48/80 (middle), or 
C5a (right) after 30 min pretreatment with live STm or PBS (control). Mean ± SEM, 
*p<0.001. 
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2.2.6 MC's Suppression is Dependent on SPI-1 T3SS and a Secreted Factor 
Inactivates MC Degranulation 
Virulence factors associated with S. Typhimurium are typically encoded by genes located 
in one or more pathogenicity islands. Therefore, we examined S. Typhimurium null mutants for 
the two best characterized pathogenicity islands, SPI1 and SPI2, as well as a double mutant 
(SPI1&SP2) for their ability to block MC degranulation. In contrast to the SPI2 mutant (ΔSPI2), 
we found that the SPI1 mutant (ΔSPI1) as well as the double SPI1&SPI2 mutant (ΔSPI1&2) failed 
to block ionomycin-induced degranulation (Figure 11A). The SPI1 T3SS translocates multiple 
effectors directly into host cells, many of which activate or impede specific cellular functions 
[67]. In addition to whole bacterial infection, we tested whether Salmonella culture supernatant 
retained the ability to suppress MCs (Figure 11B). The results indicated partial inhibition by the 
WT Salmonella culture supernatant compared to the ΔSPI1 mutant supernatant, suggesting that 
SPI1-dependent effector molecules from S. Typhimurium are secreted into culture media and 
are responsible for MC suppression.  
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2.2.7 Effector Proteins of ~50-75 kDa in Size Retain the Most Significant 
MC Suppressive Activity.  
So far, we observed that heat-killed S. Typhimurium and ΔSPI1 S. Typhimurium fail to 
suppress MCs. S. Typhimurium translocates bacterial virulence effector proteins through SPI-1 
T3SS and at least 20 effector proteins had been identified. At this point, we hypothesized that 
effector molecules having capacity to suppress MC are Salmonella secreted proteins. As we 
observed that MC suppressive effector proteins are secreted into Salmonella culture 
supernatant, we utilized column chromatography (Figure 12A), which separates these effector 
proteins based on protein size, to further identify these factors. If a collected fraction from the 
Figure 11. MC suppression is dependent on SPI-1 T3SS and its secreted factor. 
(A) MC degranulation to ionomycin after 30 min pretreatment with WT, ΔSPI1 
mutant, ΔSPI2 or ΔSPI1&ΔSPI2 STm strains and (B) MC degranulation to ionomycin 
after 2 h pretreatment with culture supernatant from WT or ΔSPI1 mutant strain, 
were measured by performing a β-hexosaminidase release assay. Mean ± SEM, 
*p<0.001. 
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elution of column chromatography were to demonstrate MC suppressive activity, we could 
narrow down the candidate factors based on size. Figure 12B shows that fraction numbers 29 
through 33, which corresponded to molecular weights from 50 to 70 kDa (Figure 12C), exerted 
the most significant suppressive effects on MC degranulation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Fractions 24-44 harboring ~50-75 kDa proteins demonstrate 
potent MC suppressive activity. 
(A) The culture media supernatant from S. Typhiumurium was separated by 
column chromatography (packed with Sephacryl S-200). Eluted fractions were 
collected and (B) used to treat RBL cells. After 1h, the degranulation response to 
ionomycin was measured with a β-hexosaminidase release assay. (C) Fractions 
24 to 44 were Coomassie stained.  
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A previous study done by the Galán group showed that S. Typhimurium secretes SPI1 
effector proteins into culture media, and five effector proteins have been identified [1] (Figure 
13A). Among them, two proteins are identified as ~50-70 kDa in size. When we connected these 
two results, the possible candidates for MC suppressive activity were Salmonella invasion 
protein B (SipB) and Salmonella protein tyrosine phosphatase (SptP). SipB is one of the 
components of the translocon complex which is assembled on the host membrane and is 
required for proper secretion from T3SS [88,89]. SptP retains protein tyrosine phosphatase 
activity to mediate host-cell recovery after bacterial invasion [90,91]. 
As we noticed in Figure 3, MC degranulation requires signaling cascades mediated by a 
tyrosine phosphorylation at each signaling molecules [16]. To inhibit overwhelming activation 
signals, MCs express endogenous tyrosine phosphatases near the plasma membrane to stop the 
tyrosine phosphorylation signaling pathway [92]. Intuitively, we hypothesized that protein 
tyrosine phosphatase activity from SptP is a potential candidate for MC suppression. Therefore, 
we tested whether Salmonella culture supernatant exhibits tyrosine phosphatase activity, which 
can interfere with tyrosine phosphorylation signaling in MCs. To inhibit tyrosine phosphatase 
activity in Salmonella culture supernatant, sodium orthovanadate was pre-incubated with MCs 
before treatment with ionomycin. The MC suppressive activity of Salmonella culture 
supernatant was reduced significantly by pre-incubation with the tyrosine phosphatase inhibitor 
(Figure 13B). Therefore, this data is consistent with the MC suppressor being SptP (Figure 13C), a 
known SPI1 effector with distinct phosphatase and GTPase activities [90].  
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Figure 13. Tyrosine phosphatase activity can inhibit MC degranulation. 
(A) Culture supernatant effector proteins of WT S. Typhimurium were separated 
by SDS-PAGE and stained with Coomassie blue. This data is adopted and modified 
from Hardt WD et al.[1]. (B) Culture supernatant from WT Salmonella was 
pretreated with sodium orthovanadate (100 μM or 10 μM) for 15 min. MC 
degranulation in response to ionomycin was measured by performing a β-
hexosaminidase release assay after 2 h incubation with pretreated culture 
supernatant. (C) Diagram of SptP with two functional domains: GTPase activating 
protein (GAP) and protein tyrosine phosphatase. Mean ± SEM, *p<0.001, **p<0.05. 
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2.2.8 Comparison of MC Tyrosine Phosphatase with SptP of Salmonella. 
We have noted that SptP shares significant homology with phosphatases naturally found 
in MCs [90,92,93]. To compare SptP in Salmonella to protein tyrosine phosphatase 6 (PTP6) and 
PTP9 in human cells including MCs, a sequence alignment and structural comparison were 
performed. Figure 14 shows that catalytic active site and functional motifs in SptP are 
structurally homologus to PTPs in human. Therefore, SptP can potentially target signaling 
molecules in MCs and interfere with tyrosine phosphorylation signaling in MCs.  
Figure 14. Sequence alignments of tyrosine phosphatase in S. Typhimurium and MCs. 
(Top) Protein tyrosine phosphatase of S. Typhimurium is sequentially conserved with PTP in 
MCs. PTPN6 and PTPN9 in MCs share the following functional and characteristic protein 
tyrosine phosphatase motifs with SptP in S. Typhimurium. Cysteine residue (red) located in 
the active site is highly conserved in the three proteins. This cysteine residue is a 
phosphotyrosine binding site in the phosphatase. The PTP signature motif (yellow), which 
has the “HCXAGXGR(S/T)” amino acid sequence in the catalytic domain, is also highly 
conserved in the three proteins. The WPD loop (blue) which phosphatases utilize to 
dephosphorylate the target is also conserved in the three proteins.  
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2.2.9 SptP-Mediated Suppression of IgE+αIgE-induced MC degranulation. 
To investigate the role of SptP in suppressing MC activity, we first compared the ability 
of WT S. Typhimurium and an isogenic ΔsptP mutant to prevent degranulation. Here, we used 
IgE+antigen as the MC stimulant because this well-characterized signaling pathway has several 
potential targets for phosphatase activity. We found that in the case of MCs pretreated with the 
ΔsptP mutant, the degranulation response to IgE stimulation was no longer inhibited and was 
even higher than that seen with IgE stimulation (Figure 15). One possibility for the enhanced 
degranulation response of ΔsptP treated MCs is that the GTPase-activating protein (GAP) 
domain of SptP also has a known ability to promote recovery of the cellular cytoskeleton after 
Salmonella-mediated invasion [91]. In the absence of a reorganized cytoskeleton, as is the case 
with the ΔsptP mutant, MCs degranulate excessively following stimulation [94].  
Next, we undertook a series of complementation studies to identify the relevant region 
in the functionally distinct domains located at either end of SptP. To distinguish between the 
effects of the GTPase-activating function of the amino-terminal region and the protein tyrosine 
phosphatase function associated with the carboxy-terminal region [90,91], we complemented 
ΔsptP S. Typhimurium with the plasmid psptPWT encoding WT sptP, psptPC481S encoding sptP with 
an inactive phosphatase domain, or psptPR209A encoding sptP with an inactive GTPase domain 
and compared the ability of the complemented strains to suppress MC degranulation (Figure 15). 
Complementation with psptPWT or with psptPR209A but not with psptPC481S inhibited MC 
degranulation in comparison to the ΔsptP mutant. These results suggest that SptP, and 
specifically the catalytic activity of its tyrosine phosphatase domain, mediates suppression of 
MC degranulation. 
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Figure 15. The protein tyrosine phosphatase domain in SptP inhibits 
MC degranulation. 
Degranulation of IgE sensitized MCs in response to antigen (Ag, TNP-OVA) 
after 45 min pretreatment with WT, ΔsptP or complemented ΔsptP strains 
(ΔsptP(psptPWT), ΔsptP(psptPC481S), or ΔsptP(psptPR209A)). Mean ± SEM, 
*p<0.001. 
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To investigate whether SptP has the inherent ability to suppress MC degranulation, we 
cloned and expressed SptP intracellularly in the RBL-2H3 MC cell by stably transfecting with 
SptP-eGFP, resulting in SptP expression in approximately 60 % of cells based on fluorescent 
activity (Figure 16A). We next examined the effects of SptP expression on the MC degranulation 
response to IgE+anti-IgE in RBL-2H3 cells. We observed that RBL-2H3 MC cells transfected with 
SptP-eGFP exhibited a significant (~60 %) reduction in degranulation compared to the control 
(Figure 16B). 
 
 
Figure 16. SptP-eGFP stable expression in MCs suppresses MC degranulation. 
(A) Expression of transduced eGFP or SptP-eGFP was assessed by green fluorescence in 
transfected cells (top). Corresponding bright field images are shown at the bottom. (B) IgE 
sensitized MCs expressing retrovirally transduced eGFP or SptP-eGFP were cross-linked 
by anti-IgE and analyzed with a β-hexosaminidase release assay.  
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Next we investigated whether applying exogenous recombinant SptP into the culture 
supernatant of MCs would block their subsequent degranulation. RBL-2H3 cells were treated 
with increasing concentrations of recombinant SptP purified from E.coli BL21 (Figure 17A) and 
then examined for their degranulation in response to different amounts of ionomycin (Figure 
17B) or to IgE+anti IgE (Figure 17C). In both cases, a modest level of inhibition of the 
degranulation response was observed. To confirm that tyrosine phosphatase activity from SptP 
mediates suppression of MC degranulation, we pretreated recombinant SptP with 
orthovanadate and examined its ability to block MC degranulation responses to IgE+anti IgE 
(Figure 17D). However, we noticed that suppression with recombinant SptP was much less than 
with S. Typhimurium by itself. We reasoned that the modest ability of recombinant SptP to block 
MC degranulation may be attributable to its relative inability to permeate MC membranes as 
this effector protein is typically introduced by S. Typhimurium directly into the MC cytosol via its 
T3SS [68]. 
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Figure 17. Introduction of recombinant SptP into MC culture media suppresses 
MC degranulation. 
(A) SptP-Hisx6 was overexpressed in BL21 E. coli and purified with a Ni column. (B 
and C) Purified recombinant SptP-Hisx6 and (D) SptP-Hisx6 with sodium 
orthovanadate (1mM) were incubated with RBL-2H3 cells. After overnight 
incubation, the degranulation response to (B) ionomycin (1µg/ml) or (C and D) anti-
IgE antibody was measured with β-hexosaminidase release assays. Mean ± SEM., 
*P<0.001, **p<0.05. 
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2.2.10 Transduction of SptP-TAT into MCs Significantly Suppresses MC 
Degranulation. 
To facilitate trafficking of SptP into the MC cytosol via non-endocytic pathways after 
exogenous treatment with SptP, we constructed membrane-permeant SptP by conjugating it to 
the short peptide RKKRRQRRR derived from the HIV TAT (transactivator of transcription) protein, 
which can translocate itself into the cytosol of various host cells [95]. To observe SptP-TAT 
penetrance into bone marrow-derived mast cells (BMMCs), we employed confocal microscopy 
to visualize the protein within BMMCs. We opted to employ BMMCs here to make the point that 
observations made using the RBL-2H3 cell line are also applicable to primary MCs. We observed 
that SptP-TAT readily entered BMMCs and could even be detected in the nuclei (Figure 18A, 
bottom). Due to its superior ability to penetrate MC membranes, we predicted that SptP-TAT 
would effectively block the MC degranulation response. We observed that in contrast to 
controls, SptP-TAT significantly inhibited IgE+anti-IgE-mediated degranulation in a dose-
dependent manner (Figure 18B). We also generated a catalytically inactive form of SptP-TAT, 
SptPC481S-TAT, to specifically ablate tyrosine phosphatase activity,  that was observed in the 
cytosol and nuclei (Figure 18A). Unlike SptP-TAT, recombinant SptPC481S-TAT was unable to 
inhibit IgE+anti-IgE-mediated BMMC degranulation (Figure 18C), confirming that SptP inhibits 
degranulation via its tyrosine phosphatase activity.  
  
39 
 
 
 
 
  
Figure 18. Treatment with SptP-TAT suppresses IgE-anti-IgE mediated MC 
degranulation. 
(A) Confocal microscopy of BMMCs exposed to SptP-TAT or SptPC481S-TAT for 4 h. MC 
granules were probed with avidin (green) and intracellular SptP-TAT was probed with 
anti-His6 (red). (B and C) Degranulation of IgE-sensitized BMMCs in response to anti-
IgE (B) after 4 h pretreatment with increasing amounts of SptP-TAT (10, 1, and 0.1 µg) 
or (C) after 2 h pretreatment with SptP-TAT (5 µg) or SptPC481S-TAT (5 µg). Scale bar 
is 20 µm. Mean ± SEM, *p<0.001, **p<0.01, ***p<0.05 
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2.2.11 SptP Impedes Tyrosine Phosphorylation Signaling in MCs 
Next, we sought to localize sites of tyrosine phosphorylation in MCs during 
degranulation and determine their activation following exposure to SptP-TAT. Confocal 
microscopy of BMMCs employing probes for MC granules and phosphotyrosine revealed that 
tyrosine phosphorylation appeared to be localized primarily to empty compartments where 
granules were housed prior to activation with IgE+anti-IgE (Figure 19, middle, arrowheads). This 
is consistent with the notion that not only is tyrosine kinase activity important in the signaling 
events leading to degranulation, but it is also important in the final stages of granule release 
[24]. We thus hypothesized that intracellular SptP could interfere with the regulation of the 
granule secretory pathway to block MC degranulation. In SptP-TAT-treated BMMCs (Figure 19, 
right), which did not degranulate following exposure to IgE+anti-IgE, no tyrosine 
phosphorylation was observed in the granule chambers, which is consistent with a lack of 
degranulation. Notably, detectable amounts of SptP were localized to the granule 
compartments. Thus, the absence of tyrosine phosphorylation proximal to sites of granule 
discharge contributes to abrogated MC degranulation in SptP-TAT-treated MCs.  
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Figure 19. SptP-TAT inhibited tyrosine phosphorylation in MC 
granule chambers to block MC degranulation. 
Morphological appearance of IgE sensitized BMMCs in response to 
anti-IgE after 2 h pretreatment with vehicle or SptP-TAT (10 µg). MC 
granules: avidin (red), SptP-TAT: anti-His6 (green), and intracellular 
tyrosine phosphorylation sites: anti-phosphotyrosine (p-Tyr) (blue) 
antibodies. Scale bars: 20 µm.  
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2.2.12 SptP Dephosphorylates SyK, an Early Signaling Substrate Following 
Receptor-mediated Activation of MCs. 
The SptP-TAT-associated absence of tyrosine phosphorylation in MCs led us to seek 
putative SptP targets in the IgE signaling pathway. Syk, a tyrosine kinase, is an important 
substrate in IgE-mediated MC degranulation [16,96], and thus we examined the effects of SptP 
on Syk activation following IgE mediated activation. SptP overexpression in transfected MCs 
markedly suppressed Syk phosphorylation following stimulation with IgE+anti-IgE (Figure 20, 
top). To further confirm the role of Syk, we also compared IgE-mediated Syk phosphorylation in 
MCs pre-treated with WT or ΔsptP S. Typhimurium. Consistent with SptP overexpression, WT S. 
Typhimurium markedly suppressed Syk phosphorylation, whereas ΔsptP S. Typhimurium failed 
to do so. Indeed, ΔsptP S. Typhimurium appeared to enhance Syk phosphorylation, indicating 
that in the absence of SptP, Salmonella might directly activate MCs and that the signaling events 
involve Syk (Figure 20, bottom). 
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Figure 20. Syk, one of tyrosine phosphorylation cascade, is the target of SptP. 
Western blots of cell preparations from IgE-sensitized RBLs that either stably 
expressed SptP-eGFP or control eGFP (top) or were pretreated with WT STm or 
ΔsptP STm for 1 h (bottom) before activation with anti-IgE. The cell preparations 
from both experiments were obtained at the indicated time points after activation 
with anti-IgE. Western blots were probed with α-p-Syk, α-Syk, and α-β-actin 
antibodies. 
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2.2.13 SptP Dephosphorylates NSF, a Signaling Substrate Implicated in 
Final Stages of Granule Release in MCs. 
We also noticed that although granules of RBL-2H3 cells were not released following 1 h 
exposure WT S. Typhimurium, they appeared to have fused with each other, resulting in 
abnormally large intracellular granules (Figure 21A, middle). However, this phenotype was not 
observed in MCs exposed to ΔsptP S. Typhimurium (Figure 21A, right). A critical determinant of 
MC degranulation is NSF, a vesicle fusion protein localized to the cytoplasmic side of the granule 
membrane [24,25]. In the steady state, NSF is typically phosphorylated which is important to 
prevent MC granules from spontaneous intracellular fusion [97]. Upon MC activation, NSF 
became dephosphorylated, promoting the fusion of granule membranes to plasma membranes 
and resulting in extracellular release of MC granules. We hypothesized that in WT S. 
Typhimurium-infected MCs, NSF is prematurely dephosphorylated, resulting in granule fusion 
without extracellular release. To validate this hypothesis, control-treated, WT, and ΔsptP S. 
Typhimurium-infected MCs were stained for NSF. In all cases, NSF colocalized to the outer 
surface of MC granules (Figure 21B). Furthermore, the granules of WT S. Typhimurium-infected 
MCs appeared to be 2-3 times the size of regular granules of control MCs and ΔsptP S. 
Typhimurium-infected MCs, suggesting intergranular fusion in the former (Figure 21B). To 
determine if intergranular fusion was associated with the dephosphorylation of NSF, we 
examined phosphorylation of NSF around MC granules and found that whereas NSF appeared 
phosphorylated around MC granules of PBS or ΔsptP S. Typhimurium-treated MCs, this was not 
the case in WT S. Typhimurium treated MCs (Figure 21B, middle). Furthermore, when we 
immunoprecipitated NSF from the three groups of MCs and probed with anti-phosphotyrosine 
antibodies on a western blot, we observed that in contrast to the other two conditions, NSF in 
WT S. Typhimurium-infected MCs was markedly dephosphorylated (Figure 21C) providing 
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support for our hypothesis of premature intergranular fusion induced by S. Typhimurium 
phosphatases. That SptP acts at sites downstream of Syk can also be inferred by the fact that WT 
S. Typhimurium, but not ΔsptP and ΔsptP(psptPC481S) blocked ionomycin induced degranulation 
(Figure 21D), which occurs downstream of receptor-mediated MC signaling events [16].  
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Figure 21. Intergranular fusion induced by WT Salmonella through 
dephosphorylation of NSF. 
(A, B) Morphology of RBLs after exposure to WT or ΔsptP STm. After 1 h treatment, (A) cells 
were stained with antibodies for fluorescence microscopy. MC granules: anti-serotonin 
(green), NSF: anti-NSF (red) antibodies and actin: phalloidin (blue). (B, C) After 1 h 
treatment, cells were treated with vanadate (100 µM) for 5 min to preserve tyrosine 
phosphorylation and (B) were stained with antibodies for fluorescence microscopy. NSF: 
anti-NSF (red) and intracellular tyrosine phosphorylation: anti-pTyr (green) and actin: 
phalloidin (blue). (C) Lysates from RBLs were analyzed by immunoprecipitation and 
immunoblotting for phosphotyrosine and NSF. Scale bar is 20 µm. (D) Degranulation 
responses of MCs to ionomycin after 30 min pretreatment with wild-type, ΔsptP, or 
complemented ΔsptP strains (ΔsptP(psptPWT), or ΔsptP(psptPC481S). Mean ± SEM, *p<0.001 
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Consistent with the β-hexosaminidase assay results (Figure 21D), the fluorescent 
microscopy images showed that WT and ΔsptP(psptPWT) S. Typhimurium retained significant 
amount of granules in the cytoplasm and were larger in size than those in control MCs when 
infected MCs were treated with ionomycin (Figure 22, top right and bottom middle). On the 
other hand, ΔsptP and ΔsptP(psptPC481S) failed to inhibit degranulation such that very few 
granules were detected in cytoplasm (Figure 22, top middle, bottom left, and bottom right), 
which is similar to the ionomycin alone-treated control.  
Figure 22. Morphology of RBLs after exposure to WT or ΔsptP mutants with 
ionomycin. 
Morphology of RBLs after exposure to WT or ΔsptP or ΔsptP(psptPWT) or 
ΔsptP(psptPC481S) S. Typhimurium. Salmonella: anti-Salmonella (red) antibody and 
granule: avidin (green) and actin: phalloidin (blue). Scale bar: 10 µm. 
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2.2.14 Yersinia Secretes YopH to Suppress MC Degranulation. 
Yersinia pestis expresses YopH, which is structurally analogous to the tyrosine 
phosphatase, SptP, present in Salmonella Typhimurium (Table 2) [90,98]. Importantly, this 
enzyme is also injected into host cells via T3SS [99]. In view of the similarities in terms of the 
structure and delivery of these phosphatases, we speculated that MC suppression may be an 
evolved virulence trait shared among sophisticated pathogens such as S. Typhimurium and 
Yersinia and hypothesized that YopH could also suppress MC degranulation. We exposed MCs to 
a WT laboratory strain of Yersinia pestis KIM5 and examined the subsequent ability of these MCs 
to mount degranulation to ionomycin. Y. pestis-exposed MCs exhibited a significantly inhibited 
degranulation (Figure 23).  
Table 2. Sequence alignments of tyrosine phosphatase in Yersinia pestis, Salmonella 
Typhimurium, and MCs. 
PTPase of S. Typhimurium is sequentially conserved with PTPase in MCs. Functional 
homologues of S. Typhimurium SptP exist in Y. pestis and MCs. YopH in Y. pestis and SHP in 
MCs share the following characteristic PTPase motif with SptP in S. Typhimurium. (1) A 
cysteine residue located in the active site (red) is highly conserved in the three proteins. 
This cysteine residue is a phosphotyrosine binding site in the phosphatase. (2) The PTP 
signature motif, which has these “HCXAGXGR(S/T)” amino acid sequence in the catalytic 
domain, is also highly conserved in three proteins. (3) The WPD loop, which phosphatases 
utilize to dephosphorylate the target, is also conserved in the three proteins.  
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To determine whether YopH was the specific Yersinia factor involved in MC suppression, 
we cloned and expressed this tyrosine phosphatase in RBL-2H3 cells. In contrast to control 
eGFP-transfected cells, MCs transfected with YopH-eGFP exhibited limited degranulation in 
response to IgE+antigen (Figure 24A). Figure 24B demonstrates the intracellular expression of 
YopH, the granulation status of treated MCs, and the tyrosine phophorylation of eGFP- and 
YopH-eGFP-transfected RBL-2H3 cells following exposure to IgE+antigen. In particular, MC 
degranulation appeared to be directly correlated with tyrosine phosphorylation in empty 
Figure 23. Yersinia pestis suppresses MC degranulation. 
Degranulation of RBLs pretreated for 30 min with PBS or Y. pestis KIM5 in response to 
ionomycin. Mean ± SEM, *p<0.001. 
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granule chambers (Figure 24B, middle, arrow heads) of IgE+antigen activated control MCs but 
not in YopH-expressing MCs (Figure 24B).  
Next, we cloned and expressed YopH as a fusion protein with TAT. To determine 
whether exogenous YopH-TAT would inhibit MC degranulation, we exposed IgE-sensitized MCs 
to increasing concentrations of YopH-TAT and examined their responses to antigen-induced 
activation. We observed a significant and dose-dependent suppression of the MC degranulation 
response to antigen (Figure 24C). Taken together, these observations indicate that YopH shares 
the ability of SptP to suppress degranulation and suggest that MC suppression may be an 
important virulence trait among host-adapted pathogens. 
In this data, we observed that YopH targeted MCs to suppress innate immunity. 
Previous studies show that YopH can suppress adaptive immunity. The tyrosine phosphatase 
activity of YopH has been known to suppress the activity of lymphocytes [100]. Specifically, 
YopH dephosphorylates adaptor proteins to interfere with the T cell receptor signaling pathway 
and prevent the development of protective immunity against Yersinia infection [101,102]. 
Altogether, Yersinia utilizes a potent tyrosine phosphatase to inactivate diverse immune cells 
and down-regulate innate and adaptive immunity.  
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Figure 24. Yersinia pestis YopH suppresses MC activation. 
(A and B) RBLs were retrovirally transduced with control eGFP or YopH-eGFP before 
IgE+antigen stimulation (Ag, TNP-OVA) and were assayed for degranulation (A) or 
subjected to confocal microscopy (B). Granules were stained with serotonin (red) and 
tyrosine phosphorylation was stained with an anti-p-Tyr antibody (blue). (C) 
Degranulation in response to IgE+Ag (TNP-OVA) RBLs following exposure to 
increasing concentrations of purified YopH-TAT. Scale bar: 10 µm, mean ± SEM, 
*p<0.001, **p<0.01. 
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2.2.15 ΔsptP S. Typhimurium Induces MC Degranulation 
To investigate the in vivo contribution of SptP to MC suppression during S. Typhimurium 
infection, we challenged the peritoneal cavities of mice with WT or ΔsptP S. Typhimurium 
(Figure 25A) and determined that MCs isolated from the peritoneal cavities exhibited widely 
different phenotypes in terms of their granulation status. MCs exposed to WT S. Typhimurium 
remained fully granulated (Figure 25A, third column), but MCs exposed to ΔsptP S. Typhimurium 
underwent extensive degranulation (Figure 25A, fourth column). This degranulation in response 
to the ΔsptP mutant when quantitated was comparable to the degranulation observed with E. 
coli J96 (Figure 25B), which was included for comparative purposes. The vacant granule 
chambers in extensively degranulated MCs stained strongly for tyrosine phosphorylation (Figure 
25A, fourth column, arrowhead), whereas granule chambers in MCs exposed to WT S. 
Typhimurium or PBS failed to exhibit tyrosine phosphorylation staining. We observed that the 
overall phosphotyrosine fluorescence in ΔsptP-infected MCs was markedly higher (Figure 25A, 
fourth column) than E. coli-infected MCs. This enhanced tyrosine phosphorylation was 
previously observed in ΔsptP-exposed MCs in vitro (data not shown), which also consistently 
exhibited higher Syk phosphorylation than IgE+anti-IgE positive control cells (Figure 20, bottom). 
This is potentially due to the fact that significantly higher degranulation was observed with 
ΔsptP S. Typhimurium than with the positive degranulation control (Figure 15).  
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Figure 25. ΔsptP Salmonella initiated phosphotyrosine signaling and 
degranulation of MCs. 
(A) 1×108 CFU WT STm, ΔsptP STm, or E. coli J96 were injected i.p. MCs were 
harvested 4 h later by peritoneal lavages, cytospun, and stained with toluidine blue for 
bright field microscopy (top) or with α-serotonin (red) for granules, and α-phosphotyrosine 
(blue) for immunofluorescence microscopy. (B) Granulated MC numbers in peritoneal 
lavages of (A) were quantified by counting partially and fully granulated MCs/field (n=3-6; 
5 random chosen fields). Wholly degranulated MCs could not be detected. n=4 mice, mean ± 
SEM, *p<0.05, **p<0.01. Scale bar: 20 µm.  
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2.2.16 ΔsptP S. Typhimurium Triggers Neutrophil Influx and Bacterial 
Clearance. 
As MC degranulation has been closely associated with neutrophil recruitment and 
subsequent bacterial clearance, we compared neutrophil responses in the peritoneum of mice 
following 4 h challenge with WT or ΔsptP S. Typhimurium. Predictably, we observed significantly 
higher neutrophil responses with ΔsptP than with WT S. Typhimurium (Figure 26A), and this 
correlated with greater clearance of ΔsptP compared to WT S. Typhimurium 24 h after bacterial 
challenge (Figure 26B), which was recovered with the complemented mutant strain 
(ΔsptP(psptPWT)) (Figure 26C, D).  
56 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 26. Enhanced neutrophil recruitment and bacterial clearance with 
ΔsptP Salmonella infection, and decreased effects with ΔsptP(psptPWT) 
Salmonella. 
(A) Assays for neutrophil recruitment (MPO) and (B) bacterial clearance (CFUs) 
were performed on lavages collected  4 h and 24 h, respectively, after i.p injection 
of 1×106 CFU WT or ΔsptP STm; n=4 mice. (C) Assays for neutrophil recruitment 
(MPO) and (D) bacterial clearance (CFUs) were performed on peritoneal fluids 
collected  4 h and 24 h, respectively, after i.p. injection of 1×106 CFU ΔsptP or 
ΔsptP(psptPWT) complemented mutant strain STm. n=4-5 mice, Mean ± SEM, 
*p<0.05. 
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2.2.17 ΔsptP S. Typhimurium Fails to Suppress MC Degranulation Induced 
by C48/80, Resulting in Neutrophil Influx and Bacterial Clearance. 
Thus far, we observed that WT S. Typhimurium suppresses MC degranulation and 
following neutrophil recruitment and bacterial clearance was affected, but ΔsptP S. 
Typhimurium fails to do so. Next, we investigated whether S. Typhimurium-mediated MC 
suppression continues even when a potent MC activator is administered. To test this hypothesis, 
mice with WT S. Typhimurium or ΔsptP S. Typhimurium i.p. infection (1h) were challenged with 
C48/80 i.p. (30min). As Figure 27 shows, both C48/80 alone and ΔsptP S. Typhimurium + C48/80 
induced heavy degranulation from peritoneal MCs (second and fourth rows, respectively). In 
contrast, peritoneal MCs from mice with WT S. Typhimurium infection failed to undergo 
degranulation even when they were exposed to C48/80 (third row). This suggests SptP mediated 
dephosphorylation is suppressing MC activation.  
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Figure 27. ΔsptP S. Typhimurium infected peritoneal MCs evoke a 
degranulation response to C48/80. 
Mice were I.P. infected with WT or ΔsptP S. Typhimurium. After 1h, the mice 
were I.P. infected with C48/80 (20 µg/mouse). After 30min, isolated peritoneal 
MCs were stained with anti-serotonin (red) and anti-pTyr antibodies (blue). 
Scale bars are 10 µm.  
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As mentioned earlier, MC degranulation leads to neutrophil recruitment and bacterial 
clearance. Therefore, we investigated whether massive suppression of MCs leads to inhibition of 
neutrophil recruitment and bacterial clearance. We compared neutrophil responses in the 
peritoneum of mice following 1 h infection with WT or ΔsptP S. Typhimurium and 4 h challenge 
with C48/80. Similar to the results from Figure 26, significantly higher neutrophil responses 
were observed with ΔsptP than with WT S. Typhimurium (Figure 28A), and this correlated with 
greater clearance of ΔsptP compared to WT S. Typhimurium 6 h after bacterial challenge (Figure 
28B). Clearance of ΔsptP S. Typhimurium was similar to that of E. coli that was used as a positive 
control for neutrophil recruitment and bacterial clearance.  
 
 
 
 
Figure 28. ΔsptP S. Typhimurium-infected peritoneal MCs evoke enhanced 
neutrophil recruitment and bacterial clearance following exposure to C48/80. 
Mice were i.p. infected with WT or ΔsptP S. Typhimurium. After 1h, the mice were i.p. 
infected with C48/80 (20 µg/mouse). Isolated peritoneal fluid was assayed for 
measuring MPO after 4h or bacterial counts after 6 h. Mean ± SEM, *p<0.01, 
**p<0.05. 
60 
2.2.18 Enhanced Neutrophil Recruitment and Bacterial Clearance 
following Infection by ΔsptP Salmonella  
Given the intrinsic ability of SptP to block MC degranulation, previous studies have not 
been able to demonstrate a specific role for MCs in combating S. Typhimurium infections in WT 
and MC-deficient mice. Indeed, when we initially compared neutrophil responses and bacterial 
clearance in WT and MC-deficient mice following intraperitoneal challenge with WT S. 
Typhimurium, we failed to notice any appreciable difference between the two strains of mice 
(Figure 5A and Figure 6).  However, based on our subsequent findings, we sought to 
demonstrate a potential MC response to S. Typhimurium by employing our ΔsptP mutant strain. 
We compared neutrophil responses and bacterial clearance of ΔsptP S. Typhimurium in WT and 
MC-deficient mice following peritoneal challenge. Neutrophil responses to ΔsptP S. 
Typhimurium were significantly more elevated in WT mice compared to MC-deficient mice 
(Figure 29, left), and this was accompanied by better clearance of ΔsptP S. Typhimurium in WT 
mice 24 h after bacterial challenge (Figure 29, right).   
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Figure 29. Enhanced neutrophil recruitment and bacterial clearance 
following infection by ΔsptP S. Typhimurium. 
Neutrophil influx (left) and bacterial counts (right) in WT and MC-deficient mice, 
following i.p. injection of 5×105 CFU ΔsptP S. Typhimurium. Mean ± SEM, *p<0.05. 
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2.2.19 S. Typhimurium utilizes SptP to inhibit MC-initiated neutrophil 
influx and bacterial clearance 
To demonstrate the potency of the MC suppressing activity of SptP-TAT, we co-
administered recombinant SptP-TAT i.p. with E. coli J96, which normally activates MCs, and 
examined neutrophil recruitment and bacterial clearance. Compared to E. coli J96 alone, E. coli 
J96 co-instilled with SptP-TAT evoked lower neutrophil responses and bacterial clearance from 
the peritoneum (Figure 30A). To verify that this weak neutrophil response was linked to MCs, we 
examined isolated peritoneal MCs and found that those from mice challenged with E. coli J96 
with SptP-TAT were non-degranulated (Figure 30B, right column) in contrast to mice challenged 
with E. coli J96 alone (Figure 30B, middle column, quantitated in Figure 30C). Furthermore, 
these non-degranulated MCs exhibited a limited degree of tyrosine phosphorylation and 
appeared to have accrued detectable amounts of SptP-TAT in their granule compartments 
(Figure 30B, right column).  
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Figure 30. Administration of SptP-TAT at sites of E. coli infection inhibits 
MC-mediated neutrophil recruitment resulting in impaired bacterial clearance. 
(A) Neutrophil influx (top) and bacterial counts (bottom) in WT mice were measured, after 
SptP-TAT (100 µg/mouse) or vehicle followed 30 min later with 1×107 CFU E. coli. MPO 
assays were performed 5 h post-infection and CFUs 24 h post-infection. (B) Morphologies of 
MCs in the peritoneal cavities of control and SptP-TAT treated mice 3 h following E. coli 
infection. MC granules: avidin (red), SptP-TAT: anti-His6 (green) and sites of tyrosine 
phosphorylation: anti-p-Tyr antibodies (blue). Scale bars: 20 µm. (C) Granulated MC 
numbers in peritoneal lavages of (B) were quantified by counting the number of partially 
and fully granulated MCs/field (n=5; 5 random chosen fields). Fully degranulated MCs could 
not be detected. 
 
 
 
 
 
 
 
 
 
 
 
 
 
65 
2.2.20 Inhibition of MC-Mediated Vascular Leakage by SptP-TAT. 
MC-mediated neutrophil recruitment is also associated with vascular leakage of serum 
components, including complement and antibodies, that can markedly impact pathogen 
persistence in tissue sites [103,104]. We sought to examine the impact of SptP on MC-mediated 
vascular leakage by assessing the tissue penetrance of intravenously administered FITC-dextran. 
Figure 31 shows the whole mount staining of mouse ears that were intradermally injected with 
vehicle or SptP-TAT followed by E. coli J96 infection. Based on the large amount of FITC-dextran 
in the perivascular space (Figure 31A and B, middle), E. coli J96-injected tissue exhibited a high 
degree of vascular leakage. A high degree of MC degranulation was also observed in this tissue. 
In contrast, no vascular leakage and MC degranulation was observed in tissue injected with E. 
coli and SptP-TAT (Figure 31A and B, right). A significant reduction in vascular leakage induced 
by SptP-TAT following E. coli J96 infection of mouse ears was quantitatively measured by 
examining extravasated Evans Blue dye (Figure 32). Additional whole mount staining revealed 
that SptP-TAT inhibited degranulation following exposure to E. coli J96 (Figure 31B) and that this 
inhibitor could be detected in the cytosol of MCs in infected tissue (Figure 33). Cumulatively, 
these findings demonstrate that SptP is a potent suppressor of MC-mediated activity, and in the 
absence of SptP, MCs would likely play an antibacterial role during infection with S. 
Typhimurium.  
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Figure 31. Vascular leakage resulting from MC degranulation following E. coli 
infection is suppressed by the administration of SptP-TAT. 
(A and B) Mouse ears were injected intradermally with vehicle or SptP-TAT (20 µg) 
and injected 1 h later with 1×106 CFU E. coli J96 at the same site and FITC-dextran 
(green) i.v. At 1 h post-infection, the ears were dissected, (A) stained with avidin 
(red) and anti-CD31 (blue), (B) stained with avidin (red) and anti-E. coli (blue), and 
whole-mounted for immunofluorescence microscopy. Scale bars: 50 μm. 
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Figure 32. SptP-TAT-suppressed MC degranulation and accompanying vascular 
leakage during E. coli infection 
(A) Vehicle or SptP-TAT or SptP-His6 or SptPC481S-TAT was intradermally injected 
into mouse ears. At 1 h post-infection, 1×106 CFU E. coli were injected at the same 
site, and Evans Blue dye (0.5%) was simultaneously injected intravenously. At 1 h 
post-infection, (A) the extravasation of Evans Blue was visualized in infected ears. 
(B) Vascular leakage was quantified by measuring extracted dye from dissected ears 
at 620 nm absorbance. Y axis values are relative to negative control. Mean ± SD. 
*p<0.01 
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Figure 33. SptP-TAT inhibited tyrosine phosphorylation signaling and 
degranulation in MCs. 
The same procedure described in Figure 31 was performed. Avidin (red), an anti-His 
antibody (green), and anti-pTyr antibody (blue) were used to stain whole ear tissue. 
The tissue was visualized by confocal microscopy. Scale bar: 50 µm. 
69 
To exclude the possibility of off-target effect of SptPWT-TAT on MCs, we verified whether 
SptPC481S-TAT can penetrate MCs and suppress MC degranulation. The results showed that 
SptPC481S-TAT could penetrate MCs (Figure 34A, middle panel) but failed to suppress MCs and led 
to significant vascular leakage at the local tissue site (Figure 34B, left panel). Additional control 
experiments with SptPWT-Hisx6 showed that penetration of SptP by itself rarely occurred (Figure 
34A, right panel) and failed to suppress MC mediated vascular leakage (Figure 34B, right panel). 
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Figure 34. SptPC481S-TAT and SptP-Hisx6 failed to suppress MCs in vivo. 
(A) BMMCs exposed to SptPC481S-TAT or SptP-Hisx6 for 4 h. Confocal microscopy 
of MCs revealed granules probed with avidin (green) and intracellular SptPC481S-
TAT probed with anti-Hisx6 (red). (B) Mouse ears were injected intradermally 
with SptPC481S-TAT (20 µg) or SptP-Hisx6 (20 µg) and 1 h later, 1×106 CFU E. coli 
were injected into the same area of each ear. At the same time a marker of 
vascular contents, FITC-dextran (green), was intravenously administered. At 1 h 
post-infection, the ears were dissected and stained to visualize MC granules: 
avidin (red) and blood vessels: anti-CD31 (blue) antibody. Tissues were whole 
mounted for confocal microscopy. 
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2.2.21 MC-S. Typhimurium Interactions Likely Occur Immediately After 
the Gut Epithelium is Breached. 
During natural infection, S. Typhimurium that successfully breach the gut epithelial 
barrier typically target the mesenteric lymph nodes, where they proliferate with limited 
interference from the host immune system [84]. However, before S. Typhimurium can reach the 
draining lymph nodes, the bacteria must circumvent an array of MCs present in the lamina 
propria of the gut epithelium. Shown in Figure 35 are sections of the cecal epithelium of mice 
challenged with PBS, WT S. Typhimurium or ΔsptP S. Typhimurium. Numerous fully granulated 
MCs were seen proximal to the epithelium in PBS or WT S. Typhimurium-challenged mice but 
not in mice challenged with ΔsptP S. Typhimurium which are incapable of suppressing MCs. 
Indeed, the apparent absence of fully granulated MCs in the cecum of ΔsptP S. Typhimurium 
challenged mice was attributable to extensive MCs degranulation induced by the many mutant S. 
Figure 35. MC degranulation in the cecum of mice infected with ΔsptP but not in WT 
Salmonella infected mice. 
Wild-type mice were pre-treated with streptomycin (20 mg/mouse) for 24 h, followed by oral 
infection with 1x108 CFU of WT or ΔsptP S. Typhimurium. After 12 h, the ceca were dissected, 
cryo-sectioned and immunostained for MCs: avidin (red), S. Typhimurium: α-Salmonella (blue), 
and epithelial cells: α-E-cadherin antibodies (green). Shown in the first panel is the cecum of 
PBS treated mice (control). Shown in the second and third panels are ceca of mice infected 
with WT or ΔsptP S. Typhimurium, respectively. Scale bar: 50 µm. 
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Typhimurium found at this site (Figure 35). 
We investigated whether these MCs in the lamina propria played a role in controlling 
bacterial numbers, thus suggesting a plausible role for S. Typhimurium-mediated MC 
suppression during natural infection. To address this question, we assessed the number of 
bacteria that reached the mesenteric lymph nodes in WT and MC-deficient mice shortly after 
oral challenge with ΔsptP S. Typhimurium, which does not suppress MCs. If gut-resident MCs 
contribute to bacterial clearance, we would expect fewer bacteria to reach the mesenteric 
nodes in MC-sufficient mice compared to their MC-deficient counterparts. We detected 
markedly greater numbers of bacteria in the immediate draining lymph nodes of MC-deficient 
mice 24 h after oral infection with ΔsptP S. Typhimurium compared to WT mice (Figure 36A). 
Because some recent studies have questioned the use of Kit-dependent MC-deficient mice 
[25,26,85], we have also included here a recently described Kit-independent inducible model of 
MC deficiency involving Cma1-cre+iDTR+ mice [25]. Using this model, we obtained very similar 
findings regarding the contribution of MCs in the clearance of ΔsptP S. Typhimurium (Figure 
36B). Additionally, we confirmed the contribution of the phosphatase domain of SptP by 
challenging WT and MC-deficient mice with ΔsptP(psptPC481S) S. Typhimurium (Figure 36C). To 
confirm that the SptP deletion was responsible for MC-dependent bacterial clearance, we also 
infected WT and MC-deficient mice with ΔsptP(psptPWT) S. Typhimurium (Figure 36D). 
Predictably, we observed that the bacterial burden in MC-sufficient mice was now comparable 
to that of MC-deficient mice. This result is also consistent with the data presented in Figure 5A 
demonstrating that the WT S. Typhimurium burden was comparable in MC-sufficient and MC-
deficient mice. Thus, MCs have the potential to regulate the colonization of the mesenteric 
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lymph nodes, which are among the first sites targeted by pathogens that successfully breach the 
gut barrier. 
 
 
 
 
 
 
 
Figure 36. Intestinal MCs reduce the bacterial burden in the mesenteric 
lymph nodes following oral infection with ΔsptP S. Typhimurium. 
CFU of mesenteric lymph nodes in streptomycin-treated (A, C, D) WT or MC-
deficient mice, (B) Cma1-cre+iDTR+ mice or WT controls after DT injections, 
following oral challenge with 5×107 CFU (A, B) ΔsptP S. Typhimurium, (C) 
ΔsptP(psptPC481S) and (D) ΔsptP(psptPWT) 24 h post-infection. *p<0.01, **p<0.05, 
N.S., not significant. 
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2.3 Discussion 
In this study, we have revealed a highly effective mechanism involving the inactivation 
of MCs employed by S. Typhimurium to elude host innate immunity, which are immune 
surveillance cells strategically located at host-environment interfaces. We demonstrated that 
unlike E. coli J96, which provoked rapid and extensive MC degranulation, S. Typhimurium not 
only failed to elicit a MC degranulation response but also prevented MC responses to a wide 
array of potent secretagogues such as IgE+antigen, a calcium ionophore and complement 
revealing a broad and powerful inhibitory activity (Figure 10, 15 and 27). This capacity to block 
MC responses to other signals is relevant during infection because even though S. Typhimurium 
do not activate MCs per se, various endogenous danger signals or alarmins are released at 
infection sites and can potentially activate MCs [105]. In vivo studies in mice revealed that this 
innate capacity of S. Typhimurium to block MC degranulation markedly reduced neutrophil 
responses and limited bacterial clearance at the infection site. This is in sharp contrast to E. coli, 
which elicited extensive MC degranulation, a strong neutrophil response, and marked bacterial 
clearance from the site of infection. This capacity to elude early innate immune responses by 
inactivating peripheral MCs may explain, at least in part, the well-recognized ability of S. 
Typhimurium to avoid clearance by the innate immune system and to disseminate rapidly from 
the site of infection to distal sites such as the draining lymph nodes and liver [84]. Our 
observation that S. Typhimurium inhibited early neutrophil recruitment is not inconsistent with 
earlier reports of strong neutrophil responses following S. Typhimurium infection [106,107]. In 
this study, we focused on a narrow window of time during the early stages of the infection 
process but observed the development of a vigorous MC-independent neutrophil response at 
sites of infection with WT S. Typhimurium after the initial lag period. Our findings imply that the 
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initial immune response to a pathogen is an important determinant of infection outcome. A 
delayed neutrophil response at the site of S. Typhimurium infection, regardless of its intensity, 
may have limited protective value because many of the bacteria are either intracellular or have 
become systemic at that point.  
The ability of S. Typhimurium to block MC activity could, at least in part, explain why 
others have not been able to demonstrate a protective role for MCs [86]. Much of our 
conclusions were based on traditional Kit mutant MC-deficient mice; however, since this model 
of MC deficiency has been recently challenged [25,26,85], we sought to confirm our findings by 
employing Kit-independent Cma1-cre+iDTR+ mice in which MC deficiency was inducible. Our 
findings utilizing this inducible model of MC deficiency corroborated our findings with Kit 
mutant mice providing further validation of our conclusions.   
S. Typhimurium-mediated suppression of MC degranulation was achieved through the 
introduction of SptP into the MC cytosol. The suppressive actions of SptP are restricted to the 
exocytic function of MCs because MCs readily internalize S. Typhimurium upon contact. SptP is a 
SPI1 effector protein with two functional domains. The N-terminal domain functions during 
pathogen entry into host cells by deactivating Rho GTPases and reversing pathogen-induced 
cytoskeletal changes following S. Typhimurium uptake [91]. The second domain, a C-terminal 
domain, comprises a protein tyrosine phosphatase reported to function late in the pathogen 
entry process when S. Typhimurium is harbored within late endosomes [108]. In these 
compartments, it is believed that SptP dephosphorylates a protein that facilitates cellular 
membrane fusion and protein degradation, enhancing intracellular S. Typhimurium replication. 
The tyrosine phosphatase domain of SptP is also thought to inactivate MAP kinase [109].  Our 
finding that the tyrosine phosphatase region of SptP mediates MC inactivation represents a 
76 
distinct function for this domain, while our work with GTPase-inactive SptP as well as YopH, 
which lacks a GTPase domain, suggests that GTPase activity is for the most part dispensable for 
MC suppression. A comparison of the primary structure of SptP with multiple tyrosine 
phosphatases found in the cytosol of MCs reveals high degree of homology [90], implying 
multiple targets for this phosphatase. Morphological studies of MCs employing pTyr-specific 
antibody probes revealed that degranulation was closely associated with phosphorylation 
events at the cell surface as well as at intracellular sites proximal to cytosolic granules. 
Phosphorylation of these proteins at both sites did not occur in the presence of SptP, suggesting 
that SptP acted at multiple sites and on multiple targets. By examining S. Typhimurium-infected 
MCs before or after activation with various secretagogues, we have been able to identify at least 
two distinct substrates for SptP.  Immunoblot analyses of S. Typhimurium-infected MCs and 
control MCs following IgE mediated activation revealed one of the intracellular targets of SptP to 
be  Syk, which is a member of the Syk/Zap-70 family and is a substrate found early in the 
signaling cascade. Microscopic and immunoprecipation studies of MCs infected with WT S. 
Typhimurium also revealed that shortly after infection MC granules spontaneously coalesced 
forming oversized granules that failed to be expelled upon subsequent exposure to potent 
secretegogues. This phenomenon was not observed with ΔsptP S. Typhimurium, indicating that 
it was an SptP-mediated activity. We have linked this intergranular fusion to SptP-mediated 
dephophorylation of NSF, a fusion protein whose functions include the prevention of homotypic 
intergranular fusion [24,93].  
Although a number MC-inactivating compounds derived from various microbes have 
been identified, including the toxic fungal metabolite gliotoxin [110,111], ES-62, a glycoprotein 
secreted by filarial nematodes [112], FK506 from Streptomyces tsukubaensis [113], and 
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cyclosporine A from Tolypocladium inflatum [114], these do not, for the most part, appear to be 
relevant to the pathogenesis of infection. Here, Our studies reveal that two highly successful 
host-adapted pathogens, S. Typhimurium and Y. pestis, share a powerful mechanism to suppress 
MC degranulation, suggesting that MC inhibition is an important virulence determinant. MCs are 
among the first immune cells encountered by these pathogens after they traverse the epithelial 
barrier. They are relatively abundant in dermal tissue, where Y. pestis is localized following 
injection by fleas, and are also common in the gut epithelium below Peyer’s patches as well as in 
the lamina propria, where they can encounter S. Typhimurium invading through M cells or gut 
epithelial cells [115]. Orally-administered S. Typhimurium that successfully breach the epithelial 
barrier traffic to the mesenteric lymph nodes, a process likely to be influenced by MC 
interactions. Indeed, significantly higher numbers of the ΔsptP mutant were present in the 
mesenteric nodes of MC-deficient mice following oral infection, implicating mucosal MCs as 
primary responders to S. Typhimurium breaching the gut epithelium (Figure 37). 
MCs and MC-like cells are found in a wide range of animal species including less evolved 
species that are devoid of an adaptive immune system. In recent years, it has become clear that 
MCs play a key role in modulating innate immune responses to various bacteria, parasites, 
viruses and fungi, suggesting that their raison d'être is the modulation of immediate and 
nonspecific immunity to microbial challenge. In view of this, it is not surprising that certain 
virulent pathogens would have evolved special mechanisms to inactivate these cells to prevent 
or delay host immune responses and promote their pathogenesis. 
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(Ando T. and Kawakami T. (Preview) [116]) 
Figure 37. Model depicting mechanism of MC Suppression by SptP derived from S. 
Typhimurium. 
(Left) WT S. Typhimurium secretes SptP into MC to suppress MC activation by 
dephosphorylating Syk and NSF. Reduced neutrophil recruitment leads to severe infection. 
(Right) ΔsptP S. Typhimurium, which lack SptP, fails to suppress MC degranulation and 
leads to the early recruitment of neutrophils to clear bacteria at an early stage of infection 
[116].  
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3. Perspective 
In this thesis I have described how pathogenic Salmonella have evolved powerful 
mechanisms to inactivate MCs which are key immune surveillance cells located in the gut as well 
as other mucosal sites. I have demonstrated that Salmonella achieve this feat by secreting a 
tyrosine phosphatase, SptP, directly into the cytosol of MCs. The translocation of SptP into MCs 
occurs via the T3SS which injects various Salmonella effector proteins via a syringe-like structure 
that appears to traverse the plasma membranes of MCs and other target cells. Once introduced 
into the MC cytosol, SptP was found to target multiple substrates involved in MC degranulation. 
One of the substrates was Syk a key conduit of early signaling from receptors located in the MC 
membrane and the other was NSF a critical mediator of the final steps of MC degranulation. 
Interestingly, SptP was found to dephosphorylate NSF resulting in premature intergranular 
fusion in MCs while it prevented phosphorylation of Syk following MC exposure to Salmonella. 
Both of these activities completely blocked the MC degranulation response to Salmonella but 
remarkably had no effect on the endocytic activities of the cell. Consequently infecting 
Salmonella were able to readily infect MCs and seek intracellular refuge in the same immune 
cells whose function it is to warn the host of the infection. Microscopic examination of the 
cecum of mice following oral challenge with Salmonella revealed that the bacteria encountered 
MCs as soon as they had circumvented intestinal epithelium in cecum (Figure 35). The 
importance of SptP in modulating the outcome of the Salmonella-MC encounter could be 
gauged by the finding that the translocation of sptP mutant Salmonella from the gut into the 
draining mesenteric lymph nodes of MC deficient mice was markedly higher than that of WT 
mice (Figure 36A).  
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While the focus of this thesis has been on MC suppression by Salmonella there are other 
pathogenic bacteria capable of targeting immune survaillance cells such as dendritic cells (DCs) 
and macrophages (Mφs) for suppression of functional activities. Not surprisingly, the strategies 
involved by these pathogenic bacteria appear, for the most part, distinct from what I have 
described here. Shown in Figure 38 are some of diverse strategies and bacterial components 
employed by various pathogens to suppress immune surveillance cells [117]. In the following 
section, I will describe briefly how two other well known host adapted pathogens, the Gram 
negative pathogen Yesinia pestis (and related species)  and the Gram positive Mycobacterium 
tuberculosis suppress DCs and macrophages.  
 
 
 
 
Figure 38. Pathogenic infection in human body. 
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3.1 Immune suppressive abilities of Yersinia and Mycobacteria 
species. 
Yersinia pestis is a Gram-negative and facultative bacteria which is the causative agent 
of plague [118].  The mortality associated with this pathogen can reach 20-50 % even with 
antimicrobial  treatment [119]. The virulence of this pathogen is associated with its multifaceted 
approach to inactivating key immune survaillance cells such as MCs, DCs and macrophages.  As 
already indicated, Y. pestis suppresses MCs by directly injecting YopH into the cytosol of these 
immune cells.  However, Yesinia spp. also target Mφs and DCs for inactivation.  This is achieved 
by the translocation of various effector proteins into the cytosol of the target cells via Yersinia’s 
T3SS. These effector proteins inactivate substrates in various signaling pathways involved in the 
secretion of key proinflammatory cytokines and chemokines. Through the secretion of  YopJ, an 
acetyltransferase, into the cytosol of Mφs, Yersinia spp. are able to block the  phosphorylation 
ability of MAPKK (Mitogen-activated protein kinase kinase). Thus leads to the blockage of the 
NF-kB signaling pathway, which in turn is critical for the secretion of many key proinflammatory 
cytokines such as TNF-α, IL-12, 15, and 18 [120,121]. While certain effectors of Yersinia such as 
YopJ block the production by macrophages of proinflammatory mediators, other bacterial 
factors appear to trigger secretion of the immunosuppressive cytokine, IL-10. Y. 
pseudotuberculosis and Y. enterocolitica can induce IL-10 production from macrophages through 
the release of virulence (V)-antigen (LcrV). When LcrV binds to toll-like receptor 2 (TLR2) on Mφs, 
IL-10 is secreted and functions as inducing distinct tolerance [122,123]. IL-10 has a potent effect 
in suppressing the production of various proinflammatory cytokines from surrounding cells 
which is beneficial for the spread of Yersinia and also in preventing the development of the 
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adaptive immune response  [122,124]. LcrV also induces IL-10 production in DCs and activates 
the JNK signaling pathway inducing these infected DCs to differentiate. 
In addition to suppressing the production of proinflammatory cytokines from DCs and 
Mφs, Yersinia also appears capable of blocking uptake by the same phagocytic cells. Through 
simultaneous injection of YopT, YopE, and YopH, Yersinia blocks various stages of the phagocytic 
process at the same time. First, the cysteine protease activity of YopT specifically cleaves Rho 
GTPases to cause depolymerization of actin filaments and disruption of the actin cytoskeleton 
[125-128]. Second, YopE activates the GTPase-activating protein (GAP) to down-regulate the 
Rho family members such as Cdc42, RhoA and Rac1 [129] which also disrupts the cellular 
cytoskeleton [130]. Third, YopH dephosphorylates the Fyn-binding protein (FYB) to deform the 
peripheral focal complexes [131] needed for bacterial uptake.  Thus, through the secretion of 
multiple effectors Yersinia can negatively regulate the functions of key immune surveillance cells 
in the microenvironment that it occupies in the host permitting bacterial colonization and 
spread within the host.  
Mycobacterium tuberculosis causes tuberculosis, one of the top 10 causes of human 
morbidity and mortality worldwide. If tuberculosis patients are not treated, fatality rates can 
reach up to 50 % [132]. Although different Mycobacterium spp. causes distinct diseases, they 
tend to share many virulence mechanisms. For example, M. tuberculosis, M. leprae and M. 
ulcerans all seem to suppress mediator release from immune surveillance cells which they 
interact with. They typically also invade and survive intracellularly within these cells. In their 
intracellular niches these bacteria can avoid the host’s immune defenses as well as antibiotic 
treatment resulting in chronic infections.  
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 M. tuberculosis which primarily targets Mφs but also infects DCs suppresses these cells, 
at least partially with a mannose-containing glycoprotein (ManLAM) that is a mycobacterial cell 
wall component. ManLAM activates the DC-SIGN signaling pathway which prevents DC 
maturation [133] resulting in limited DC trafficking to draining lymph nodes and limited adaptive 
immune responses. Activation of the DC-SIGN pathway results in the activation of the 
serine/threonine kinase Raf-1. This signaling substrate acetylates NF-κB subunit p65 resulting in 
enhanced secretion of IL-10 which is strongly anti-inflammatory [134]. M. tuberculosis persist in 
the host by infecting and replicating in phagosomes of Mφs. Infected Mφs form granulomas 
which serve to encapsulate bacteria within host tissue. Promoting intracellular survival are 
several secreted virulence proteins  such as SapM, a lipid phosphatase, which dephosphorylates 
phosphatidylinositol 3-phosphate (PI3P) and recruits certain specific proteins into the 
phagosome in order to avoid acidification and subsequent fusion with lysosomes [135-137]. The 
phagosome of M. tuberculosis has diminished vacuolar H+ATPase and low level of lysosomal 
hydrolase which is favorable for bacterial survival. In DCs, prevention of phagosome maturation 
severely limits antigen presentation resulting in limited adoptive immune responses in the host 
[138-140]. Cumulatively, due to their distinct and powerful immunsuppressive actions on DCs 
and Mφs, mycobacteria are able to successfully establish chronic infections in the host which 
are very difficult to eradicate. 
3.2 Coopting MC suppressing properties of bacteria for therapy. 
As indicated earlier in this thesis, MCs can be prominent players in various chronic and 
harmful inflammatory disorders such as asthma, allergy, psoriasis, arthritis, inflammatory bowel 
diseases, etc. When more is known regarding how different microbes suppress MCs, it is 
conceivable that certain microbes or their products can be utilized to ameliorate some of these 
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chronic inflammatory diseases. For example, it is conceivable that administering cell-permeable 
forms of SptP into inflammatory sites will impair mediator secretion from MCs and even other 
immune cells to abrogate inflammation. Its potential usage could be comparable to the 
administration of Botox, a neurotoxin derived from Clostridium botulinum into human facial skin 
to reduce wrinkle formation [141,142]. The toxin reduces abnormal muscle contraction by 
blocking release of acetylcholine from neurons, which normally signals muscle contraction. 
Importantly the effect of Botox can last several months and therefore the frequency of its 
administration is limited.  With the therapeutic success of even a highly toxic agent such as 
Botox, there is currently great interest in the therapeutic use of other bacterial products which 
are much less toxic [143].  
Some microorganisms or their products are already being used clinically for therapy, 
unrelated to their MC-suppressing properties, but when their MC suppressing property is also 
considered, they could have additional clinical uses. For example, the Lactobacillus and 
Bifidobacterium species are frequently being applied as probiotics in patients with inflammatory 
diseases in the gut. In view of the capacity of probiotic bacteria in suppressing IgE-mediated MC 
responses [144-146], these bacteria or their products may potentially also be used to temper 
the pathology associated with allergic inflammation. The fungal metabolite Cyclosporin A is 
routinely used as a potent nonsteroidal immunosuppressive drug in patients following organ 
transplant [147]. In view of its potent MC suppressing actions [147], this drug could be 
repurposed for the treatment of various inflammatory disorders where MCs play a key part.  The 
innate capacity of various microbes to suppress MC function may therefore have significant 
therapeutic promise.  
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3.3 Concluding Remarks 
For many decades the study of bacterial pathogenesis has centered around virulence 
factors that promote bacterial adherence and colonization of mucosal surfaces as well as factors 
that promote bacterial entry and survival in various host cells.  It is only recently that the 
immunomodulatory role of bacterial pathogens was recognized.  That successful pathogens 
need to repress or avoid the host’s wide array of innate and adaptive immune responses in 
order to survive is now being recognized as a key virulence trait. Through investigating the 
various strategies and the underling molecular basis for bacteria-mediated immune suppression 
or avoidance, it will be possible to develop appropriate counter measures or vaccines to combat 
microbial pathogens in the future. These strategies will become even more important with the 
overuse of antibiotics and the resulting emergence of multi-resistant bacteria in our midst.  
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4. Materials and Methods 
4.1 Bacterial strains and culture.  
S. Typhimurium SL1344, SL1344-derived Tn5 transposon insertion mutants in SPI1, SPI2, 
and SPI1&2 were gifts from Dr. Alejandro Aballay, Duke University. SB300, and its sptP deletion 
mutant, SB749, were gifts from Dr. Jorge E. Galán, Yale University. ΔsptP(psptPWT), 
ΔsptP(psptPC481S), and ΔsptP(psptPR209A) were generated in this study. Other strains used include 
E. coli J96 and CI5, a Gram-positive clinical isolate Staphylococcus aureus strain 54 (Duke 
University Medical Center), and a WT laboratory strain of conditionally virulent and naturally 
occurring Yersinia pestis KIM5. Bacteria were grown for 15 h, non-shaking, in Luria-Bertani (LB) 
(Gibco) broth at 37˚C. 25 µg/ml kanamycin was added for transposon mutants, 100 µg/ml 
streptomycin for SB300 and SB749, and 100 µg/ml carbenicillin for complemented strains.  
4.2 Mice.  
6- to 8-week-old C57BL/6 mice were purchased from the National Cancer Institute. MC-
deficient Wsh mice (KitW-sh/KitW-sh) and their congenic littermate controls were purchased from 
Jackson Laboratories. To induce MC depletion, eight-week-old Cma1-cre+iDTR+ (a gift from Dr. 
Axel Roers, University of Technology, Dresden) and wild-type littermates received five i.v. 
injections of 100 ng DT per mouse in a week.  Mice were housed in the Duke University Vivarium 
and provided food and water ad libitum. All experiments were performed according to protocols 
approved by the Duke University Institutional Animal Care and Use Committee.  
4.3 Animal infections and CFU counts.  
Mice were infected intraperitoneally with the indicated CFU of various strains of S. 
Typhimurium, or E. coli J96 in 100 µl of sterile PBS. At the indicated times, mice were euthanized, 
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5 ml of sterile, ice-cold PBS was injected into the peritoneal cavity, and the abdomen was gently 
massaged. The collected peritoneal fluid was analyzed for MC degranulation, neutrophil influx, 
or bacterial counts. The detailed procedure of oral infection to streptomycin-pretreated mice 
was described [148]. Briefly, mice were pretreated with 20 mg streptomycin prior to infection 
with 5×107 CFU of ΔsptP or its complemented mutant S. Typhimurium. At various times, mice 
were euthanized and mesenteric lymph nodes homogenized in 0.1% Triton X-100 per PBS. 
Lysates were plated on MacConkey agar with or without 50 μg/ml streptomycin and incubated 
overnight at 37˚C for CFU. 
4.4 Cell culture.  
RBL-2H3 cells were grown in MEM (Gibco) supplemented with 15% FBS (GEMINI Bio-
Products). BMMCs were prepared by flushing femurs from C57BL/6 mice with cRPMI (10% FBS, 
100 U/ml Pen Strep, 25 mM HEPES, 2 mM L-glutamine, 1 mM sodium pyruvate, 1 mM 
nonessential amino acids (all from Gibco)). LAD2 cells were grown in StemPro-34 (Gibco) (2.6% 
StemPro-34 nutrient supplement, 2 mM L-glutamine, 100 U/ml Pen Strep, and 100 ng/ml SCF 
(R&D systems)). Flushed bone marrow were cultured for 12 weeks in cRPMI containing 5 ng/ml 
IL-3 and 5 ng/ml SCF (R&D systems). All cells were culture at 37˚C in a humidified water-jacketed 
incubator under 5% CO2 / 95% air atmosphere.  
4.5 β-hexosaminidase assay.  
RBLs or BMMCs or LADs were plated in 96-well plates on the day before the experiment. 
For experiments with IgE-stimulation, cells were sensitized overnight with 1 µg/ml IgE (BD 
Biosciences). RBLs were exposed to bacteria as indicated in Tyrode’s buffer for 30 min. In 
secondary stimulus experiments, cells were stimulated either with ionomycin (1 μg/ml) or 
C48/80 (10 μg/ml) or C5a (0.5 ng/ml) or TNP-OVA (10 ng/ml) (all from Sigma) or anti-IgE 
88 
antibody in Tyrode’s buffer at 37˚C. The detailed procedure of β-hexosaminidase assay was 
described previously [51]. 
4.6 Microscopy.  
Peritoneal lavage fluids were cytospun by using Cytospin3 (Shandon) on Superfrost Plus 
glass slides (VWR). Mesentery was carefully dissected and dried on slides. To stain MCs, freshly 
prepared Carnoy’s fixative (ethanol, chloroform, and glacial acetic acid) and 0.5% Toluidine blue 
were used. Fully degranulated MCs could not be detected, because there were no granules left 
in MCs to be detected. Peritoneal lavage cells or BMMCs were cytospun and fixed in 4% PFA. 0.1% 
saponin (Sigma) in 1% BSA in PBS was used to permeabilize cells and dilute antibodies. For 
whole mount staining of ear tissue, dissected ears were fixed in 4% PFA (2 h) and permeabilized 
with 0.3% Triton X-100 in 1% BSA in PBS containing 5% goat serum. Cells or tissues were 
incubated with primary antibodies:  antibody to His6 (Roche), E. coli, p-Tyr, CD31 (BD 
Biosciences), and serotonin (DakoCytomation). The secondary antibodies with FITC or Cy3 or 
A647-conjugated anti-mouse, A647-conjugated anti-rabbit, DyLight 649-conjugated anti-rat, Cy-
3-conjugated anti-mouse antibodies (Jackson Immuno Research) and TRITC or FITC conjugated 
avidin (Sigma) was incubated. Nikon ECLIPSE TE200 microscope (Nikon) was used to observe 
confocal images. To prevent spectral overlapping between individual fluorescent emission 
signals, a channel-series approach of EZ-C1 Nikon software was utilized. 
4.7 Myeloperoxidase activity assay.  
Cells derived from peritoneal lavage were resuspended in hexadecyltrimethyl 
ammonium bromide (Sigma) in phosphate buffer and lysed by multiple freeze-thaw cycles. 
Lysed cells were centrifuged and supernatant was mixed with o-dianisidine and hydrogen 
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peroxide in phosphate buffer. Activity was measured during 1 min interval three times at 450 
nm. 
4.8 Construction of SptP plasmids and transfected cell lines.  
Full-length SptP was amplified from SL1344 and cloned into pWSK29, pLEGFP-C1 
(Clontech), and pET 28b TATv1 (a gift from Dr. Steven F. Dowdy, University of California, San 
Diego). psptPC481S, psptPR209A, EGFP-SptPC481, and SptPC481S-TAT plasmids were constructed by 
site-directed mutagenesis using PCR. Sequences of PCR primers were described in Table 3. For 
complementation, ΔsptP S. Typhimurium was transformed by electroporation with 100 μg/ml 
carbenicillin for selection. For stable expression of EGFP-SptPWT or EGFP-SptPC418S, viral particles 
were produced from the AmphoPack-293 cell line (BD Biosciences) and infected into RBLs with 
geneticin selection (Invitrogen).   
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Table 3. PCR Primer Sequence 
 
4.9 SptP-TAT purification and Column Chromatography 
SptP-TAT and SptPC481S-TAT were expressed in BL21-Gold (DE3) competent cells (Agilent 
Technologies) grown in LB media, purified by His GraviTrap TALON (GE Healthcare life Sciences) 
chromatography and dialyzed in PBS with 0.1% 2-mercaptoethanol. After concentration, protein 
samples were stored in 10% glycerol at -80˚C. Vehicle was PBS with 0.1% 2-Mercaptoethanol 
and 10% glycerol. To separate proteins from Salmonella culture media, gel-filtration column was 
utilized. Salmonella cultured media was collected and concentrated by molecular cut-off column 
Plasmids Primers  
pWSK29 
psptP  
5'-CGG GAT CCC ATG CTA AAG TAT GAG GAG AG-3'  
5'-CCC AAG CTT TCA GCT TGC CGT CGT CAT AA-3'  
psptPC481S  
5'-ATA AGC ATT TAC CGA TGA TTC ATT CCC TGG GC-3'  
5'-CCG GTT CTT CCC ACT CCG CCC AGG GAA TGA AT-3'  
psptPR209A  
5'-GCT TCA GGT AAC GGC CCG CTG GCC TCA TT-3'  
5'-TCT GTA AAT TCG TCA TTA ATG AGG CCA GC-3'  
pLEGFP-C1  psptP  
5’-CCA AGC TTC GAT GCT AAA GTA TGA GGA GAG AA-3’  
5’-CGC GGA TCC GCG TCA GCT TGC CGT CGT CAT AAG C-3’  
pET 28b 
TATv1  
psptP  
5’-CGC GGA TCC GAT GCT AAA GTA TGA GGA GAG AAA AT-3’  
5’-CCC AAG CTT TCA GCT TGC CGT CGT CAT AAG CAA C-3’  
91 
(10kDa). The concentrated culture supernatant was loaded onto the gel-filtration column which 
was packed with sepharyl S-200 resin. Eluted fractions were collected and analyzed for assays. 
4.10 Statistical analysis.  
Results were analyzed with one-way ANOVA and Tukey’s post-test or two-way ANOVA 
or the Mann-Whitney t-test as appropriate with Prism (GraphPad) software. All in vitro 
experiments were repeated with three independent conditions. Differences between groups 
were considered significant at p<0.05. All error bars represent SEM. 
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